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Abstract 
The Cannabis Use Identification Test-Revised (CUDIT-R) is a brief cannabis misuse-screening tool, 
which is widely used to identify cannabis use problems. The CUDIT-R is widely accepted and 
psychometrically reliable within a clinical population. However, it is unclear if these same cut-offs are 
applicable in a community population. Additionally, the proposed changes in the DSM-5 introduce a 
new classification system and severity threshold system for identifying the severity of cannabis use 
disorder. Accordingly, the current CUD1T-R cut-off scores will no longer mirror the DSM severity 
thresholds. Consequently, the current study aims to identify community based cut-off scores that are 
consistent with the DSM-5 cannabis use disorder severity thresholds, as well as an indication of 
possible psychosocial difficulties experienced at these levels of cannabis use severity. 
Method and Results 
The sample for analysis consisted of 310 Australian cannabis users. Receiver operating characteristics 
(ROCs) was the statistical procedure used to determine cut-off scores that produced maximum 
sensitivity and specificity, when calibrated against the DSM-IV and DSM-5 cannabis use severity 
thresholds, and the Severity of Dependence Scale. The results identified that a CUD1T-R cut-off of 13 
was the optimal threshold for cannabis dependence (DSM-1V); a cut-off score of 9 was the optimal 
threshold for mild cannabis use disorder (DSM-5), a cut-off score of 13 was identified for moderate 
and severe cannabis use disorder (DSM-5), and finally, a SDS cut-off score of 10 was identified. 
Discussion 
The current study has identified community based CUDIT-R cut-off points that are consistent with the 
DSM-5 cannabis use disorder severity thresholds and has provided an indication of possible 
psychosocial difficulties experienced by cannabis users at varying CUDIT-R cut-off points, which 
may inform clinical intervention. 
Chapter 1: Introduction 
In Australia, cannabis is the most commonly used illicit drug with an estimated 1.9 
million people over the age of 14 years old using cannabis in the past 12 months (Australian 
Institute of Health and Welfare [AIHW], 2010). Approximately 38% of Australians aged 14 
years and over have tried or used cannabis at some time in their life (AIHW). The AIHW also 
identified that the most common frequency of use was once or twice a year (35%) and 13% 
of recent users reported daily cannabis use. As a result of the high prevalence and frequency 
of cannabis use in Australia, it is necessary that healthcare professionals have comprehensive, 
practical, and robust cannabis screening instruments. This allows healthcare professionals to 
identify the frequency and severity of use, the potential associated harms and risks, to provide 
more thorough assessment where required, and to implement interventions that better manage 
the severity of use and frequency of use where possible (Dawe, Loxton, Hides, Kavanagh, & 
Mattick, 2002). Targeted, routine, and opportunistic screening with early intervention for 
cannabis use problems has potential for enormous gains in public health (Bashford, Flett, & 
Copeland, 2010). 
Screening instruments, such as the Cannabis Use Identification Test-Revised (CUDIT-R) 
have been widely used to identify cannabis use problems. The CUDIT-R has established cut-
off scores that inform severity and frequency of cannabis use. However, these cut-off scores 
are mirrored on the current Diagnostic and Statistical Manual of Mental Disorders (DSM-IV) 
substances abuse classification system, which has been updated in the DSM-5 to reflect the 
addictive properties of cannabis and the presence of cannabis withdrawal, which until now 
has not been recognised. Therefore, it is necessary to review the existing CUDIT-R cut-off 
scores in order to keep them consistent with the DSM. 
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Diagnosing Cannabis Use Disorders 
Diagnosis typically involves a systematic evaluation of signs, symptoms, and laboratory 
data as these relate to the history of the patients present illness or condition (Roffman et al., 
2006). The purpose of diagnosis is to provide the clinician with a logical basis for planning 
treatment and estimating prognosis (Roffman et al.). When a substance use disorder is 
suspected an individual requires a formal diagnosis to exclude false positive and baseline 
cases (Roffman et al.). The two dominant standard systems used worldwide to classify and 
diagnose cannabis use disorders are current versions of the DSM and the International 
Classification of Diseases (ICD-10) (Bashford, 2007). Both systems identify a substance use 
disorder with common criteria (Bashford, 2007). The ICD-10 (WHO, 2010) is used mainly 
outside the United States and covers the entire range of medical disorders, of which one 
specific section covers psychiatric disorders (Hasin et al., 2006). The ICD-10 section on 
psychiatric disorders includes substance use disorders (Hasin et al.). The ICD-10 diagnostic 
criterion defines two disorders in substance use disorders, dependence and a secondary 
category called harmful use. While the DSM classification system is the preferred diagnosis 
system in Australia, it is also important to understand the ICD classification system. 
The DSM-IV (American Psychiatric Association, APS, 2004) and ICD-10 (The World 
Health Organisation, WHO, 2010) diagnostic criteria define two substance use disorders, 
namely substance dependence and a secondary category, called substance abuse in DSM-IV 
and harmful use in ICD-10 (Hasin, Hatzenbuehler, Keyes, & Ogburn, 2006). DSM-IV and 
ICD-10 also provide substance-specific intoxication and withdrawal symptoms, and methods 
for diagnosing substance-induced psychiatric disorder (Hasin et al.). Each system requires at 
least three criteria to be met in order to diagnose dependence, and co-occurrence of criteria 
over a 12-month period. The DSM-IV and ICD-10 criteria for substance dependence are 
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similar, and include criteria for tolerance, withdrawal, continued use despite problems and 
various indicators of impaired control (see Table 1, Hasin et al.). Specifically, both systems 
identify tolerance as a need for increased amounts to achieve desired effects and both identify 
withdrawal as involving taking a substance to relieve or avoid withdrawal symptoms. 
Additionally, both systems identify impaired control, neglect of activities, time spent in 
substance-related activities, and continued use despite problems as dependence criteria. 
However, the ICD-10 identifies a physiological withdrawal state and compulsions whereas 
the DSM-IV does not. The DSM-IV identifies cannabis abuse in more depth than the ICD-10. 
The main difference between the two diagnoses is that 'desire or sense of compulsion to 
smoke' is an ICD- 10 criterion, but is not stated directly in DSM-IV (for a full review see 
Hasin et al., 2006). However, this is likely to change with the proposed revisions in the DSM-
5. 
Table 1 
Comparisons Between the ICD-I0 and DSM-IV 
Dependence 	 ICD-10 
	
DSM-IV 
12 
Clustering criteria 
Tolerance 
Withdrawal 
Impaired control 
Neglect of activities 
(a) Three or more of the 
following six symptoms 
occurring together for at 
least one month, or if <one 
month, occurring together 
repeatedly within a 12 
month period. 
Need for significantly 
increased amounts to 
achieve intoxication or 
desired effect or markedly 
diminished effects with 
continued use of the same 
amount of substance. 
A physiological 
withdrawal state of the 
characteristic withdrawal 
syndrome for the 
substance, or use of the 
substance (or closely 
related) to relieve or avoid. 
Difficulties controlling use 
in terms of onset, 
termination, or levels of 
use; using in larger 
amounts or over a longer 
period than intended; or a 
persistent desire or 
unsuccessful efforts to 
reduce or control use. 
Important alternative 
pleasures or interests given 
up or reduced because of 
use; or 
(a) A maladaptive pattern 
of substance use, leading 
to clinical significant 
impairment or distress as 
manifested by three or 
more of the following 
seven symptoms occurring 
in the same 12-month 
period. 
Need for markedly 
increased amounts of 
substance to achieve 
intoxication or desired 
effect, or markedly 
diminished effect with 
continued use of the same 
amount of substance. 
The characteristic 
withdrawal syndrome from 
the substance or same 
substance (or a closely 
related) is taken to relieve 
or avoid withdrawal 
symptoms. 
Persistent desire or one or 
one or more unsuccessful 
efforts to cut back or 
control use. Using in larger 
amounts or over a longer 
period that the person 
intended. 
Important social, 
occupational, or 
recreational activities 
given up or reduced 
because of use. 
A great deal of time spent 
in activities to obtain, to 
Time spent in substance 	A great deal of time spent 
in activities necessary to  
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related activity 	 obtain or use it to recover 	use or to recover from the 
from its effects. 	 effects of use. 
Dependence 
Compulsion 
Abuse 
Strong desire or sense of 
compulsion to use. 
(a) (harmful use) Clear 	(a) 
evidence that 
substance use 
contributed to physical 
or psychological 
harm, which may lead 
to disability/adverse 
consequences; 
(b) the nature of harm 
should be clearly 
identifiable (and 
specific); 
(c) the pattern of use has 
persisted for at least 
one month or has 
occurred repeatedly 
within a 12 month 
period; 
(d) symptoms do not meet 
criteria for any other 
mental or behavioural 
disorder related to 
substance in the same 
time period (except for 
acute intoxication). 
ICD-10 DSM-IV 
None 
a maladaptive pattern 
of substance use, 
leading to clinically 
significant impairment 
or distress as 
manifested by at least 
one of the following 
occurring within a 12- 
month period 
Recurrent use of 
substance resulting in a 
failure to fulfil major 
role obligations at 
work, school, or home. 
Recurrent use in 
situations in which it is 
physically hazardous 
(e.g., driving an 
automobile or 
operating a machine 
when impaired by 
substance use) 
recurrent substance-
related legal problems 
(e.g., arrest for related 
disorderly conduct). 
Continued substance 
use despite having 
persistent or recurrent 
social or interpersonal 
problems caused by or 
exacerbated by the 
effects of substance 
(e.g., arguments with 
spouse about 
consequences of 
intoxication) 
symptoms have never 
met criteria for 
substance dependence 
(b) 
(Source: Hasin et al., 2006) 
Cannabis and the DSM-5 
The proposed DSM-5 manual intends to restructure the approach of diagnosing cannabis 
abuse and substance dependence by identifying four cannabis diagnoses under the heading of 
Cannabis Related Disorders. The purpose of diagnosis for cannabis use disorders is to 
provide clear descriptive categories to enable clinicians to identify presenting problems and 
communicate succinctly about them (Dawe et al., 2002). According to the DSM-5, Cannabis 
Related Disorders consists of Cannabis Use Disorder, Cannabis Intoxication, Cannabis 
Withdrawal, and Cannabis-Induced Disorder not otherwise classified. The identification of 
Cannabis Use Disorder removes the problems associated with the abuse/dependence 
distinction in the DSM-IV and also includes withdrawal criteria. One of the major problems 
the new classification system will aim to reduce is the problem with diagnostic orphans, 
which are sub-clinical individuals who display one or two dependence symptoms, but do not 
meet full diagnostic criteria for a DSM-IV cannabis abuse or dependence diagnosis. The 
DSM-5 diagnostic criteria for Cannabis Use Disorder are shown in Table 2a (APA, 2012). 
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Table 2a 
The DSM-5 Diagnostic Criteria for Cannabis Use Disorder 
A. A problematic pattern of cannabis use leading to clinically significant impairment or 
distress, as manifested by at least 2 of the following, occurring at any time in the same 12- 
month period: 
1. Cannabis is often taken in larger amounts or over a longer period than was intended 
2. There is a persistent desire or unsuccessful efforts to cut down or control cannabis use 
3. A great deal of time is spent in activities necessary to obtain, use or recover from use 
of cannabis 
4. Recurrent cannabis use resulting in a failure to fulfil major role obligations at work, 
school, or home (e.g., repeated absences or poor work performance; absences, 
suspensions, or expulsions from school; neglect of children or household) 
5. Continued cannabis use despite having persistent or recurrent social or interpersonal 
problems caused or exacerbated by the effects of the substance (e.g., arguments with 
spouse about consequences of intoxication, parent punishment for use, loss of friends 
or partners) 
6. Important social, occupational, or recreational activities are given up or reduced 
because of cannabis use 
7. Recurrent cannabis use in situations in which it is physically hazardous (e.g., driving 
an automobile or operating a machine when impaired by use) 
8. Cannabis use is continued despite knowledge of having a persistent or recurrent 
physical or psychological problem that is likely to have been caused or exacerbated 
by the substance 
9. Tolerance, as defined by either of the following: 
a. A need for markedly increased amounts of cannabis to achieve intoxication or 
desired effect 
b. Markedly diminished effect with continued use of the same amount of cannabis 
10. Withdrawal, as manifested by either of the following: 
a. The characteristic withdrawal syndrome for cannabis (refer to Criteria A and B of 
the criteria sets for Withdrawal from the specific stimulant) 
b. The same (or a closely related) substance is taken to relieve or avoid withdrawal 
symptoms 
11. Craving, a strong desire or urge to use cannabis 
(Source: APA, 2012) 
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Severity of dependence is one of the most important dimensions in assessment and is 
crucial for intervention decisions in screening, treatment matching, and goal selection. 
However, severity thresholds are not included in the DSM-IV or the ICD-10. As a result of 
the conceptualisation of the dependence syndrome as dimensional, severity thresholds have 
been included in the DSM-5 diagnosis of Cannabis Use Disorder. Specifically, the DSM-5 
introduces a severity scale for classifying severity of cannabis use: 0 to 1 criteria (no 
diagnosis); 2 to 3 criteria (Mild Cannabis Use Disorder); 4 to 5 criteria (Moderate Cannabis 
Use Disorder); and 6 or more criteria (Severe Cannabis Use Disorder). Severity scales (such 
as those proposed in the DSM-5) have been found to be effective in distinguishing the 
seriousness of use (Langenbucher, Morgenstern, & Miller, 1995). 
The development of the severity thresholds is beneficial, as it allows for the acquisition 
of knowledge about the natural course of dependence and informs how the disorder may be 
treated (Dawe et al., 202). These severity thresholds are consistent with all the Substance Use 
Disorders identified in the DSM-5. The proposed cut-off scores have been shown to yield 
similar prevalence and high concordance in relation to the combined DSM-IV substance 
abuse and dependence diagnoses, while removing the problems associated with the 
abuse/dependence distinction, such as the problem with 'diagnostic orphans' (Degenhardt, 
Lynskey, Coffey, & Patton, 2002). The proposed changes may therefore be better able to 
identify sub-clinical cannabis related problems. Establishing thresholds beyond which 
cannabis use is problematic is useful for healthcare professionals as it will better enable them 
to provide the appropriate services and interventions to people to prevent future risk of harm 
from cannabis use, which may prevent escalation of further problems (Degenhardt et al., 
2002). 
17 
Cannabis Withdrawal 
Despite the omission of cannabis withdrawal from the DSM-IV, it has been commonly 
reported among non-clinical (Swift, Hall, Didcott, & Reilly, 1999; Swift, Hall, & Copeland, 
2000) and clinical (Budney,  Radonovich, Higgins, & Wong, 1998; Copeland, Swift, & Rees, 
2000) samples of cannabis users. It has also been shown in basic neuroscience, observed in 
human experimental studies, including inpatient and outpatient settings (Haney, Ward, 
Corner, Foltin, & Fischman, 1999), precipitated in animals using a cannabinoid antagonist 
(Haney et al; Lichtman & Martin, 2002; Budney Vandrey, Hughes, Moore, & Bahrenburg 
2007), and in epidemiological studies (Budney et al., 1998). Data from these four areas of 
scientific research corroborate each other and interweave fluidly to dispel the myth that 
cannabis is not addictive and does not result in withdrawal properties. Additionally, animal 
and human inpatient and outpatient studies have clearly demonstrated that withdrawal can 
occur following abrupt cessation of cannabis or tetrahydrocannabinol (THC) administration 
(Budney et al., 2007). Accordingly the DSM-5 includes criteria for Cannabis Withdraw is 
shown in Table 2b. 
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Table 2b 
The DSM-5 Diagnostic Criteria for Cannabis Withdrawal 
A. Cessation of cannabis use that has been heavy and prolonged (i.e., usually daily or almost 
daily use over a period of at least a few months. However, withdrawal symptoms have been 
observed among those with less frequent, but chronic use patterns) 
B. Three (or more) of the following develop typically within a week after Criterion A: 
1. Irritability, anger, or aggression 
2. Nervousness or anxiety 
3. Sleep difficulty (e.g., insomnia, disturbing dreams) 
4. Decreased appetite or weight loss 
5. Restlessness 
6. Depressed mood 
7. At least one of the following physical symptoms causing significant discomfort: 
stomach pain, shakiness/tremors, sweating, fever, chills, or headache 
C. The symptoms in Criterion B cause clinically significant distress or impairment in social, 
occupational, or other important areas of functioning 
D. The symptoms are not associated with another medical condition and are not better 
accounted for by another psychiatric disorder 
(Source: APA, 2012) 
Cannabis Intoxication is the third disorder identified in the DSM-5 and refers to the 
clinically significant maladaptive behavioural or psychological change that develops during, 
or shortly after cannabis use. 
Cannabis Screening 
While the proposed changes in the DSM-5 reduce the problems associated with 
diagnostic orphans and identify cannabis withdrawal as a true symptom, a diagnosis using the 
DSM-5 alone is time consuming and not well suited to primary medical practice or general 
clinical assessments. Accordingly, brief preliminary screening instruments are more 
practically useful in determining the early stages of cannabis related problems and cannabis 
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dependence (Bashford, 2007). Screening is also important as it helps identify potential sub-
threshold diagnoses and points of intervention to prevent further dependence trajectory. 
Screens can also be self-completed and therefore do not have to be administered by a 
health professional, which may inform individuals of their potential risk and motivate them to 
seek help if they are concerned with the result (Bashford, 2007). Therefore, it is important 
and necessary to have screens that can assist in screening appropriately for potential harmful 
use and associated risk. It is important that cannabis use cut-off scores identified on screens 
are comparable to the criteria and severity thresholds proposed in the DSM-5. This provides 
consistency in understanding the potential severity of use, and in managing the individual's 
use and potential psychosocial associated impacts of use. 
Given the rates of cannabis use identified in the general Australian population, and the 
potential risks associated with cannabis use, some of the most recent research related to 
cannabis has focused on early problem use identification (Bashford, 2007). In a clinical 
setting, cannabis-screening instruments are an economic and time efficient means of 
identifying people who are 'at-risk' of cannabis related problems and harms prior to using 
more extensive diagnostic instruments (Piontek, Kraus, & Klempova, 2008). Screening does 
not enable a clinical diagnosis to be made or determine the complete profile of a person's 
psychosocial functioning, but it does help to identify individuals who may have a cannabis 
use problem that warrants further assessment (Bashford). 
Cannabis screening is also important for early detection of cannabis use problems, as 
early screening can prevent the escalation of further cannabis use and related problems by 
providing intervention as early as possible to prevent the trajectory to further dependence and 
more serious and chronic harms (Bashford, Fleet, & Copland, 2010). Screening instruments 
are particularly useful as many cannabis users who experience cannabis related problems do 
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not seek treatment for their cannabis use, but alternatively seek assistance to better manage 
related problems, such as problems with sleep, interpersonal relationships, and mood 
disturbances (Bashford et al.). Therefore, if healthcare professionals are aware that these 
screens are available, then individuals presenting for other related problems, such as sleeping 
difficulties, can be screened for cannabis use problems in a brief, inexpensive, and efficient 
manner (Bashford, 2007). 
Until recently there were few effective cannabis screens available as many of the original 
screens were developed on the template of existing alcohol or other drug screens. 
Consequently, many of these initial cannabis screens were too lengthy, complex, or otherwise 
unsuitable (Bashford, 2007). Fortunately the recent and ongoing development of a small 
range of cannabis specific screens has allowed for more effective screening of cannabis 
related problems (Bashford). Table 3 outlines some of the most widely used cannabis screen 
including, the Severity of Dependence Scale (SDS; Gossop et al., 1995); the Cannabis Use 
Disorders Identification Test (CUDIT; Adamson & Sellman, 2003); the Problematic Use of 
Marijuana (PUM; Okulicz-Kozaryn, 2007); and the Cannabis Abuse Screening Test (CAST; 
Legleye, Karila, Beck, & Reunaud, 2007). 
It is important to note that Table 3 does not identify all cannabis screening instruments 
available and that there are additional scales that measure cannabis related problems, 
including the Marijuana Screening Inventory (MSI), the Substance Dependence Severity 
Scale (SDSS), and the Cannabis Problems Questionnaire (CPQ). Theses scales have been 
identified as more extensive and too time consuming for epidemiological purposes (Piontek 
et al., 2008). For a fully comprehensive overview of all cannabis screens available see, 
Screening and Assessment for Cannabis use Disorders (Bashford, 2007). 
Table '3 
Cannabis Screening Instruments 
Cannabis Screen Items 	Description 	 Psychometric properties 
SDS 
CUDIT-R 
PUM 
CAST 
5 	• Valid 
• Reliable 
• Tested with adolescents, 
adults, and psychiatric 
populations 
• Separate norms available 
for adults and adolescents 
10 	• Self-report for adults 
• Cut-off norms available 
8 	• Self—report for youth 
• Assess for cannabis 
dependence 
6 	• Self—report for 
adolescents and adults. 
• Validated and reliable 
• Sensitivity = 64-86%, 
specificity =82-94% in 
adults; and sensitivity = 
64% and specificity =94% 
(cut-off = 4) in nonclinical 
young people. 
• Sensitivity =73%; 
specificity = 95% 
• Overall positive predictive 
validity = 84% 
• Internal consistency = .92 
• Sensitivity = 80.9%; 
specificity = 87.5% 
• Reliability: Cronbach's 
alpha = 0.81 
• Sensitivity = 92.9%; 
specificity = 81.4% (cut 
off=4); positive predictive 
value = 45.8% 
(Source: Copeland, Frewen, & Elkins, 2009; Legleye, 2007). 
An advantage the CUDIT has over alternative screening instruments, such as the SDS, 
CAST and CUPIT, is that it is able to measure patterns of cannabis use and related problems 
(Adamson et al., 2010). The CAST is ill-served to screen for current cannabis use disorder as 
it enquire about lifetime use, in contrast to the focus on the past 6 months for the CUDIT and 
past year for the SDS (Adamson et al.). The CUDIT is widely used amongst healthcare 
workers in Australia. Accordingly, Adamson et al. recommends that the CUDIT be used 
when an instrument is required to screen for harmful and hazardous cannabis use and is 
identified as a preliminary step in determining the early stages of cannabis related problems 
and cannabis dependence during the preceding 6 months (Adamson & Sellman, 2003; 
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Bashford et al., 2010). To complete the CUDIT participants are required to read a statement 
and circle the answer, which corresponds to their pattern of use. The CUDIT can be self-
administered or verbally administered by a healthcare worker. Each question is scored from 0 
to 4, with an example item being "How often were you stoned for six or more hours?" 
The CUDIT 
The CUDIT (Adamson & Sellman, 2003, see Appendix A) is a 10-item instrument that 
was developed by modifying the Alcohol Use Disorders Identification Test (AUDIT, 
Saunders, 1993; see Table 4). The AUDIT assists practitioners to identify whether a person 
has hazardous (or risky) drinking, harmful drinking, or alcohol dependence (WHO, 2001). 
Hazardous drinking is a pattern of alcohol consumption that increases the risk of harmful 
consequences for the user or others (WHO). Harmful use refers to alcohol consumption that 
results in adverse consequences to physical and mental health (WHO). Alcohol dependence is 
a cluster of behavioral, cognitive, and physiological phenomena that may develop after 
repeated alcohol use (WHO). 
The validity of the AUDIT was computed against a composite diagnosis of harmful use 
and dependence (WHO, 2001). In the test development samples, a cut-off value of 8 points 
yielded sensitivities for the AUDIT for various indices of problematic drinking that were 
generally in the mid 0.90's. Specificities across countries and across criteria averaged in the 
0.80's on the AUDIT (WHO). In comparison to other screening tests, the AUDIT has been 
found to perform equally well or at a higher degree of accuracy across a wide variety of 
criterion measures (WHO). AUDIT scores were found to correlate well with measures of 
drinking consequences, attitudes toward drinking, vulnerability to alcohol dependence, 
negative mood states after drinking, and reasons for drinking (WHO). 
Table 4 
The Alcohol Use Disorders Identification Test (AUDIT) 
1 	How often do you have a drink containing alcohol? 
2 	How many drinks containing alcohol do you have on a typical 
day when you are drinking? 
3 	How often do you have 6+ drinks on one occasion 
4 	How often have you found that you were not able to stop 
drinking once you had started? 
5 	How often have you failed to do what was normally expected 
from you because of drinking? 
6 	How often have you needed a first drink in the morning to get 
yourself going after a heavy drinking session? 
7 	How often have you had a feeling of guilt or remorse after 
drinking? 
8 	How often have you been unable to remember what happened 
the night before because of your drinking? 
9 	Have you or someone else been injured as a result of your 
drinking? 
10 	Has a friend or health worker been concerned about your 
drinking or suggested you cut down? 
Hazardous 
alcohol use 
Hazardous 
alcohol use 
Hazardous 
alcohol use 
Dependence 
syndrome 
Dependence 
syndrome 
Dependence 
syndrome 
Harmful 
alcohol use 
Harmful 
alcohol use 
Harmful 
alcohol use 
Harmful 
alcohol use 
  
(Source: Saunders et al., 1993) 
In translating the AUDIT for use with cannabis, item modification was done carefully to 
match closely the AUDIT content (Adamson & Sellman, 2003). For items 1, 4, 5, 6, 7, 9 and 
10 the word "alcohol" was replaced with "cannabis". For items 2 and 3 number of standard 
drinks was replaced by number of hours "stoned". For item 8, instead of asking about 
frequency of being "unable to remember what happened the night before because you had 
been drinking", participants were asked for the frequency of "problems with your memory 
or concentration after using cannabis" (Adamson & Sellman). 
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A further change from the AUDIT was that participants were asked to relate the 
questions to the past 6 months in order to coincide with the 6-month duration of other 
baseline and follow-up measurements (Adamson & Sellman, 2003). The AUDIT items apply 
to the current time (items 1 to 3), the past year (items 4 to 8), or provide response options for 
past year or prior to the past year (items 9 and 10). The classification of scores also differs 
from the AUDIT, which recognises three domains (e.g., hazardous alcohol use, dependence 
symptoms, and harmful alcohol use). 
The ability of the CUDIT to accurately screen for cannabis use and dependence was 
examined using 53 participants who were originally recruited for a study that aimed to 
identify the effectiveness of a randomised controlled trial of Motivational Enhancement 
Therapy (MET) for people diagnosed with mild to moderate alcohol dependence (Sellman, 
Sullivan, Dore, Adamson, & MacEwan, 2001). Sellman et al's results found that in patients 
with mild to moderate alcohol dependence, MET is more effective for reducing unequivocal 
heavy drinking than either a feedback/education session alone or four sessions of nondirected 
reflective listening. This population was used to develop the CUDIT as they reported 
smoking cannabis in the past six months (in addition to having a primary diagnosis of alcohol 
dependence). Additionally, for these 53 participants a current mood disorder was identified in 
6% of subjects while for anxiety disorders the current rate was 17%. A current diagnosis of 
either conduct disorder or antisocial personality disorder was identified in 15% of the sample. 
Within a clinical treatment population the CUDIT demonstrates adequate reliability, with a 
reported Cronbach's Alpha of 0.84 (Adamson & Sellman, 2003). The CUDIT is also able to 
reliably identify individuals with cannabis use disorders, with acceptable specificity (95%) 
and sensitivity (73%) at a cut-off of 8 (Adamson & Sellman). However, it is not clear if the 
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CUDIT achieves the same reliability in a community-based population, as specific studies 
examining the CUDIT's performance have mostly been conducted on clinical populations. 
The CUDIT's performance has been examined in clinical populations in New Zealand 
(Adamson & Sellman, 2003). Adamson and Sellman's research focused on the ability of the 
CUDIT to accurately screen for cannabis abuse or dependence, which was examined in a 
New Zealand clinical sample that reported some cannabis use over the preceding 6 months (n 
= 53). The CUDIT was superior to the frequency measure, achieving positive predictive 
power of 85% and sensitivity of 73% at a cut-off of 8. Adamson and Sellman concluded that 
these results indicate the practicality of a screening measure for identifying cannabis use 
disorder in at risk clinical populations. 
The CUDIT's performance has also been examined with a clinical population in a Swiss 
population survey (Annaheim, Rehm, & Gmel, 2008). According to Annaheim et al's results 
obtained from their Swiss population, Item 9 (injuries) and Item 2 (usual hours being stoned) 
on the CUDIT, which were derived from the AUDIT did not perform well. These results 
were consistent with those obtained from a French clinical sample (Guillem et al., submitted). 
Specifically, these items were rarely endorsed by cannabis users, showed low scale 
correlations, and did not increase Cronbach's a when included. Therefore, these items proved 
unsuitable for the detection of problematic cannabis use. Accordingly, Annaheim, Scotto, and 
Gmel (2010) completed a study aimed at improving the psychometric properties of the 
CUDIT, achieved by replacing these items (Item 2 and 9) that performed poorly, with new 
items that specifically addressed cannabis use. 
Annahiem et al (2010) collected CUDIT data from the 2007 Swiss Cannabis Monitoring 
Study, which included a sub-sample of 558 (total n= 5722) aged 13 to 32. The general 
population sample consisted of 12% daily or almost daily users; 29% used cannabis on a 
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weekly basis (e.g., one to five times per week), 34% on a monthly basis, and 25% had used 
cannabis at least once during the last six months, but not on a monthly basis (Annaheim et 
al.). Four new items were added to the original CUDIT. Psychometric properties of all 14 
items, as well as the dimensionality of the supplemented CUDIT were then examined using 
Item Response Theory. Results indicated the unidimensionality of CUDIT and an 
improvement in its psychometric performance when three original items (usual hours being 
stoned, injuries, and guilt) were replaced with new items (motives for using cannabis, missing 
out on leisure time activities, and difficulties at work/school). However, improvements were 
limited to cannabis users with a high problem score. For epidemiological purposes, any 
further revision of CUDIT should therefore include a greater number of 'easier' items. 
Compared to the original version, the revised CUDIT has slightly improved model fit when 
measured by CFI (0.94 versus 0.93), and internal consistency (Cronbach's Alpha) also 
increased (from 0.76 to 0.80). 
In response to the concerns raised by Annahiem et al. (2008; 2010), regarding the 
psychometric properties and item appropriateness of the CUDIT, Adamson, Kay-Lambkin, 
Baker, Lewin, Thornton, Kelly, and Sellman (2010) revised the CUDIT. A revised CUDIT-R 
was developed, which contains eight items, comprising of four original CUDIT items and 
four new items (see Table 5). The sample recruited for the development of the CUDIT-R 
consisted of 144 patients who were originally taking part in a clinical trial of Cognitive 
Behavioural Therapy for depression and substance misuse and recruited from the self-help for 
alcohol, drug use, and depression (SHADE) study (Kay-Lambkin, Baker, Lewin, & Kelly, 
2008). All participants met the criteria for current depressive symptoms, scored 17 or greater 
on the Beck Depression Inventory II (BDI-II; Beck, 1993), and had concurrent hazardous use 
of alcohol, cannabis and/or amphetamines (Adamson et al., 2010). Participants were 
administered the trial CUDIT-R at intake, 6 months, and 12 months. At each time point 
formal diagnoses of cannabis abuse or dependence were made using the Structured Clinical 
Interview for DSM Disorders (SCID). 
Receiver Operator Characteristic (ROC) analysis was used in order to determine, which 
cut-off score allowed for the best trade-off between sensitivity and specificity, when 
calibrated against the presence or absence of a DSM-IV diagnosis of cannabis use problems. 
Following this statistical procedure, a cut-off score of 13 was proposed as indicating possible 
cannabis use disorder and a score of 8 indicating hazardous cannabis use, producing high 
sensitivity (91%) and specificity (90%). According, to Adamson et al. the 8 item CUDIT-R 
has improved performance over the original scale and appears well suited to the task of 
screening for problematic cannabis use within a clinical population. 
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The CUDIT (Adamson & Sellman, 2003) The CUDIT-R (Adamson et al., 2010) 
How often do you use cannabis? 
How many hours were you "stoned" on a 
typical day when you had been using 
cannabis? 
How often were you "stoned" for 6 or more 
hours? 
How often during the past 6 months did you 
find that you were not able to stop using 
cannabis once you had started? 
How often during the past 6 months did you 
fail to do what was normally expected from 
you because of using cannabis? 
How often during the past 6 months did you 
needed to use cannabis in the morning to get 
yourself going after a heavy session of using 
cannabis? 
How often during the past 6 months did you 
have a feeling of guilt or remorse after using 
cannabis? 
How often in the past 6 months have you had 
a problem with your memory or 
concentration after using cannabis? 
Have you or someone else been injured as a 
result of your use of cannabis over the past 6 
months? 
Has a relative, friend or a doctor or other 
health worker been concerned about your use 
of cannabis or suggested you cut down over 
the past 6 months?  
How often do you use cannabis? 
How many hours were you "stoned" on a 
typical day when you had been using 
cannabis? 
Deleted in the CUDIT-R 
How often during the past 6 months did you 
find that you were not able to stop using 
cannabis once you had started? 
How often during the past 6 months did you 
fail to do what was normally expected from 
you because of using cannabis? 
How often in the past 6 months have you 
devoted a great deal of your time to getting, 
using, or recovering from cannabis? 
Deleted in the CUDIT-R 
How often in the past 6 months have you had 
a problem with your memory or 
concentration after using cannabis? 
How often do you use cannabis in situations 
that could be physically hazardous, such as 
driving, operating machinery, or caring for 
children? 
Have you ever thought about cutting down, 
or stopping, your use of cannabis? 
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Table 5 
The Items of the CUD IT and the CUDIT-R 
Bruno, Gomez, de Graaff, Matthews, and Adamson, (2009) conducted a study that aimed 
to examine the psychometric properties of the 8-item CUDIT-R, and to assess its convergent 
and concurrent validity. According to the results of the study the CUDIT-R demonstrates 
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good psychometric properties within their sample of very high frequency 'hard' substance 
consumers , the CUDIT-R is unidimensional, and is able to differentiate between cannabis 
users who experience few problems and those who experience notable problems with their 
use (Bruno et al.). The scale has also demonstrated acceptable levels of test-retest reliability 
(Bruno et al.). Accordingly, Bruno et al. concluded that the CUDIT-R is a useful clinical tool 
for identifying problematic cannabis use. 
However, according to Adamson et al. (2010) the findings of the CUDIT-R validation 
study are limited by the nature of the sample, in that it was a treatment population, with all 
patients having a mood disorder at entry into the study, as well as high rates of alcohol and 
amphetamine use. However, the nature of the treatment population used in the validation of 
the CUDIT-R is not unlike other cannabis use populations, where poly-drug use and mood 
disorder are high (Adamson et al., 2006; Weaver et al., 2003). Adamson et al. identify that 
the CUDIT-R may not be representative of a community population and acknowledges that 
the existing CUDIT-R psychometrics have only been obtained from a clinical treatment 
population. Therefore, while the proposed thresholds correctly identify problematic cannabis 
use within a clinical population it is unclear if a community population endorses the items in 
the same way. Accordingly, it is recommended that community data be collected for the 
CUDIT-R to identify the severity cut-off scores within this population (Adamson et al., 2008) 
as it is necessary to norm the CUDIT-R on a community population in order to be confident 
in interpreting the results of the CUDIT-R obtained from this population. 
The CUDIT-R cut-off scores are designed to identify cannabis dependence on the DSM-
IV criteria of substance use dependence. Accordingly, while the CUDIT-R is helpful in 
identifying individuals with problematic cannabis use problems, the screening instrument 
fails to account for people who are at risk or who experience mild problems with cannabis 
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use. In order to make the CUDIT-R more consistent with the proposed DSM-5 classification 
system it is beneficial to develop cut-off scores that are mirrored on the DSM-5 severity of 
use thresholds, specifically, Mild Cannabis Use Disorder (2 to 3 criteria), Moderate Cannabis 
Use Disorder (4 to 5 criteria), and Severe Cannabis Use Disorder (6 or more criteria). This is 
likely to be beneficial, as it would enable the CUDIT-R to correctly identify sub-threshold 
cannabis related problems, and consequently be consistent with the proposed classification 
system. 
Clinically Interpreting CUDIT-R Scores 
Screening instruments are beneficial as they can provide an indication of the presence of 
a possible diagnosis, which requires further investigation. However, they do not provide 
information about the unique features of an individual's problem (Dawe et al., 2002) and 
while higher consumption levels generally predict greater problem severity, even irregular 
users can experience substantial psychosocial impairment (Bashford, 2007). It is necessary 
and important for screening instruments to provide some indication of possible psychosocial 
functioning at identified cut-off scores to better inform clinical intervention and an indication 
of potential problems with continued use. 
Specifically, it would be beneficial and helpful for screening instruments to include an 
indication of the potential risk and likelihood of cannabis use on psychological distress, 
psychological wellbeing, and physical and mental health. Furthermore, it would be useful if 
screening instruments such as the CUDIT-R provided a percentage of individuals who 
experience deficits in these areas at varying levels of cannabis use severity. Accordingly, it is 
essential to supplement a cannabis-screening instrument with additional information about 
psychosocial factors that may exacerbate or affect the severity of use, or be useful in 
implementing management strategies and interventions (Dawe et al., 2002). 
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This is a particular limitation identified with the CUDIT-R. Specifically, the CUDIT-R 
does not provide a clinical interpretation of the scores obtained in terms of the possible and 
likely psychosocial difficulties. Accordingly, it is likely that many healthcare professionals 
who use the CUDIT-R within a community population are unsure as to how to interpret 
CUDIT-R score beyond the proposed labels of "hazardous cannabis use" and "possible 
cannabis use disorder". Healthcare professionals using the CUDIT-R would benefit from an 
indication of possible psychosocial difficulties experienced at varying levels of cannabis use 
severity and inform the implementation of possible interventions, which may prevent 
escalation of further problems (Degenhardt et al., 2002). 
Moreover, assessment of the specific types of adverse health and psychosocial 
• consequences, their number, frequency, and severity is crucial for understanding the nature 
and extent of impact on the individuals' life, and planning appropriately targeted intervention 
strategies (APA, 2000; Bashford 2007). 
Accordingly, it is not only essential that the CUDIT-R is mirrored against the DSM-5 
Cannabis Use Disorders criteria to identify severity and frequency of use and dependence, but 
that these thresholds would also benefit from an indication of potential psychosocial 
difficulties associated with severity of cannabis use and dependence. Providing an indication 
of typical psychosocial functioning at CUDIT-R cut-off points may also inform the delivery 
of appropriate interventions prior to the onset of substance use disorder, enable clinical 
interventions to be implemented at early stages of risk to prevent future risk, provide 
important information about possible interventions and services to reduce harm of use, and 
provide interventions to promote positive psychological and psychosocial functioning (Thake 
& Davis, 2011). 
32 
The CUDIT was developed as a brief cannabis screen, which has recently been revised 
and published as a psychometrically reliable cannabis-screening instrument. However, as 
with all new instruments, the CUDIT-R has several shortcomings. Accordingly, the current 
research aims to elevate the limitations associated with the CUDIT-R to improve its 
population application and usefulness, clinical interpretation, and preliminary diagnostic 
reliability. To achieve this, the current research aims to: 
I. Test the validity of the cut-off point for DSM-IV cannabis dependence within a 
community sample. 
2. Determine cut-off scores (mild dependence, moderate dependence, and severe 
dependence) on the CUDIT-R, which are consistent with the DSM-5 interpretation of 
cannabis use disorders within a community sample. 
3. Provide an indication of possible psychosocial difficulties experienced at varying 
CUDIT-R thresholds, which may better inform healthcare professions of possible 
associated difficulties and indicate possible areas for intervention. 
Chapter 2: Method 
Participants 
Three hundred and ten participants who met the research criteria consented to 
participate in the study. Inclusion criteria included: being an Australian resident, being over 
the age of 18, and having smoked cannabis in the past 6 months. Participants were recruited 
through several mediums. Firstly, the research was advertised using posters (see Appendix 
B1). Two versions were circulated in popular community areas such as the University of 
Tasmania, in local clubs and pubs, in public toilets, and in cafes in Tasmanian towns 
including Hobart, Launceston, Devonport, Burnie, George Town, and Beaconsfield. This 
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allowed for a comprehensive community sample. The posters were circulated once a week for 
22 weeks to ensure maximum exposure of the research. The second method of recruiting 
participants, which was initiated alongside the poster advertising, was through online 
cannabis user forums. To achieve this, the researcher created an account with Australian 
based cannabis user forums, including the Marijuana Forum (www.themarijuanaforum.com ) 
and Australia's Cannabis Culture Forum (http://ozstoners.com/index.php)  and advertised the 
research on the forum research wall. The forums were frequented each week. The blurb used 
to advertise the research on this forum is included in Appendix B2. 
The research was also advertised using online social networks, including Facebook 
and Twitter. The blurb used to advertise on Facebook was the same as that used on the online 
forum (see Appendix B2). Recruitment on Twitter involved sending the research information 
to specific cannabis 'clubs', such as `@cannabisstrains' who then shared the research with 
their 'followers'. The research was circulated on Facebook and Twitter weekly. Letters were 
sent to every university psychology faculty across Australia. These letters were addressed to 
the Head of School requesting support to advertise the research within their faculty (see 
Appendix B3 for a copy of the letter). The research was also advertised in the Alcohol, 
Tobacco, and other Drugs Council Tasmania Inc. (ATDC) electronic newsletter (May 2012; 
see Appendix B4). This newsletter is circulated amongst all ATDC subscribers. Press media 
was also used to advertise the research. Specifically, an advertisement was placed in the July 
edition of Warp magazine advertising the research. The press media was printed as an A6 
size ad in the magazine (see Appendix B5) and ran for one edition of the magazine. 
Materials 
An online questionnaire package (see Appendix Cl) was activated and hosted by 
LimeSurvey Version 1.92+. Several measures were used to create the online questionnaire 
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package, which included measures of cannabis use, cannabis outcomes, cannabis 
expectancies, outcome measures, and drug use. Questions related to cannabis use focused on 
the frequency, quantity, administration, and cost of cannabis use. 
Cannabis outcome measures. 
The CUDIT-R 
The CUDIT-R (Adamson & Sellman, 2003, see Appendix C2) is an eight-item self-
report cannabis misuse-screening instrument employing a 5-point Likert Scale. The CUDIT-
R exhibits improved psychometric properties (Adamson, 2010) over the original scale 
(CUDIT, 2003) and appears well suited to the task of screening for problematic cannabis use 
within a clinical population. The maximum possible score is 40, with a cut-off score of 8 
indicating 'hazardous' cannabis use, and a cut-off score of 12 or more indicating "possible 
cannabis use disorder" for which further intervention may be required (Adamson, 2009). 
These CUDIT-R questions have been validated for their ability to produce DSM-IV 
diagnoses in the context of clinical samples and it is highly likely that the CUDIT-R would be 
appropriate in epidemiological work based on the AUDITs appropriateness in 
epidemiological work (Barbor, Higgins-Biddle, Saunders & Monteiro, 2001). The CUDIT-R 
items were used to create DSM-IV and DSM-5 clinical cut-off scores that mirror the DSM-5 
and DSM-IV diagnosis of cannabis use disorder and cannabis dependence respectively. 
The DSM-IV and DSM-5. 
The DSM-IV and DSM-5 (APA) criteria for cannabis dependence (DSM-IV) and 
substance use disorder (DSM-5) were included in the questionnaire, based on items used in 
the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC, see Chen 
et al., 2006 for further information on the NESARC methodology and findings) and in the 
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Composite International Diagnostic Interview - Substance Abuse Module (CIDI-SAM). The 
NESARC included a series of questions that were adapted and modified from the Alcohol 
Use Disorder and Associated Disability Interview Schedule-IV (AUDADIS-IV). The 
questions in the NESARC are relevant to the assessment of the new DSM-V diagnosis of 
substance use disorder and were therefore deemed appropriate to be included as DSM-IV and 
DSM-5 criteria in the current survey. A total of 34 questions were included. Accordingly, the 
community based cut-off scores were mirrored against DSM-5 criteria to provide an accurate 
representation of an individual's potential risk. 
The severity of dependency scale. 
The SDS (Gossop et al., 1995, see Appendix C4) provides a brief measure of the 
psychological aspects of dependence experienced by users of various types of illicit drugs, 
such as control over cannabis use, anxiety about use, and difficulty stopping (Gossop et al.). 
In the current study the SDS was used to establish an individual's severity of cannabis 
dependence and as a means of concurrent validation. The severity of dependence is 
established by rating each answer on a scale of 0 to 3. The range of possible scores on this 
questionnaire is between 0 and 15 indicating minimum to maximum severity of cannabis 
dependence respectively (Gossop et al.). The SDS has cut-off scores for adults (SDS = 3) and 
adolescents (SDS = 4) (Gossop et al.). The SDS cut-off of 3 was used in the current research 
to make predictions of cannabis dependency. 
Psychosocial outcome measures. 
The kessler psychological distress scale. 
The Kessler Psychological Distress Scale (K-10, Kessler et al, 2002, see Appendix 
C6) is a 10-item questionnaire intended to yield a global measure of psychological distress 
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based on questions about symptoms of anxiety and depression that an individual has 
experienced in the most recent 4-week period. The K-10 measures clinical distress and is 
important to include as it can indicate how cannabis use may predict levels of psychological 
distress, and accordingly relates directly to clinical outcome of cannabis use. Scores range 
from 10 to 50. People who score under 20 are likely to be well (i.e., have no mental disorder), 
score 20 to 24 are likely to have a mild mental disorder, score 25 to 29 are likely to have 
moderate mental disorder, and score 30 and over are likely to have a severe mental disorder 
(Andrews & Slade, 2001). Thirteen percent of the adult population will score 20 and over and 
about 1 in 4 people who are seen in primary health care will score 20 and over (Andrews & 
Slade). 
Short form-12 health survey. 
Short Form-12 Health Survey (SF-12, Ware, Kosinski, & Keller, 1996, see Appendix 
C7) includes 12 questions taken from the original SF-36 Health Survey. The SF-12 includes 8 
concepts commonly represented in health surveys: physical functioning, role functioning 
physical, bodily pain, general health, vitality, social functioning, role functioning emotional, 
and mental health. Results are expressed in terms of two meta-scores: the Physical 
Component Summary (PCS) and the Mental Component Summary (MCS). The SF-12 is 
scored so that a high score indicates better physical functioning. Scores from normative 
samples, range from 0 to 100 (M= 50; SD= 10), where a score of zero score indicates the 
lowest level of health measured by the scales and 100 indicates the highest level of health 
(Ware et al.). In the current study cut-off scores were identified for the PCS at one SD above 
and below the normative sample M and for the MCS at one SD above and below the M (Ware 
et al.). 
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The psychological wellbeing inventory. 
The Psychological Wellbeing Inventory (PWI, Cummins, 2006, see Appendix C9) 
is a 12-item scale, which consists of 6 dimensions, including autonomy, environmental 
mastery, personal growth, positive relations with others, purpose in life, and self-acceptance. 
The self-report scale assesses an individual's wellbeing at a particular time within each of 
these six dimensions. Higher scores on each scale indicate greater wellbeing on that 
dimension. Scores range from 0 (extremely dissatisfied) to 100 (extremely satisfied). The 
normative M range for Australia is 73 to 76 points (Cummins & Lau, 2010). In the current 
study cut-off scores were identified against one and two SD below and above the normative 
sample. 
Procedure 
The Tasmanian Human Research Ethics Committee Tasmania Network approved a 
full ethics application for this research (Appendix D1). A pilot study was conducted using 
postgraduate students and research staff at the University of Tasmania, which improved the 
quality and efficiency of the survey as several items were removed due to being repetitive or 
irrelevant and several new items were added, which were identified as more relevant to the 
current study. The pilot study as ensured that scales within the survey was presented in a 
logical progression. The survey was then activated online and advertising commenced for the 
recruitment of participants. From the advertisement, participants were instructed to navigate 
their way to the online survey using the URL/web address provided and asked to complete 
the online survey. The survey was timed in the pilot study to take approximately 40 minutes 
to complete. Participants were asked to complete all questions, but were given the option of 
skipping questions that they did not want to respond to. The online survey was the only task 
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required of participants. Accordingly, once participants had completed the survey their 
participation in the study was concluded. 
In appreciation of participant's time, those who completed the survey were then 
invited to be included in an anonymous prize draw to win one of three $500 JB Hi-Fi 
electronic gift vouchers. The prize invitation (Appendix D4) form was hosted on a separate 
website to the research survey. In this way, submitted entries were not connectable with 
individual surveys. A dump of the data was reviewed in August and used in the final analysis. 
Once the survey was deactivated the prize draw was drawn and the JB Hi-Fi electronic gift 
vouchers were sent directly to the prize-winner's anonymous email address. 
ROC analysis 
ROC analysis (Coombs, Dawes, & Tversky, 1970) was used to determine optimal cut-
off points for the CUDIT-R that would distinguish cannabis dependent cases from non-
dependent cases as validated against the 'gold standard' diagnostic systems, namely, the 
DSM-IV and the DSM-V and on the SDS. ROC analysis was employed as it represents an 
integration of accuracies across a range of possible cut-off scores, or more specifically, across 
different levels of sensitivity (i.e., the screening instrument correctly identifies subjects with a 
current diagnosis) and specificity (i.e., it correctly identified those who do not meet 
diagnostic criteria) (Rey, Morris-Yates, & Staainslaw, 1992; Rice & Harris, 1995; Swets, 
1992). For this study, Youden's Index was used to calculate a cut-off score that can be used 
to identify a cut-off score for the DSM-IV, DSM-5 (mild), DSM-5 (moderate), DSM-5 
(severe), and the SDS (outcome measure). Youden's Index is a single statistic that captures 
the performance of a diagnostic test (Youden, 1950). 
A ROC curve is obtained by plotting sensitivity against the false positive rate for all 
possible cut-off points of the instrument (Rey et al., 1992). A crucial competent of ROC is 
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the area under the curve (AUC). According to Hsu (2002, p. 414), the AUC "reflects the 
probability that a randomly selected person from one population will have a scale score that 
exceeds that of a randomly selected person from another population". The performance of an 
instrument is determined by the magnitude of the AUC, specifically, the higher the AUC, the 
better the instrument is at distinguishing between cases (Brown & Davis, 2006). For 
example, an AUC of 1 is considered to be a perfect test, 0.80 to 0.90 is considered to be a 
good discriminator, and 0.5 and below represents a relatively inefficient measure (e.g., the 
measure does not perform better than chance) (Swets, 1996). 
ROC also calculates the Positive Predictive Value (PPV) and the Negative Predictive 
Value (NPV) of the cut-offs. The PPV of a cut-off refers to the proportion of individuals 
classified as cases that have received the diagnosis, while the NPV refers to the proportion of 
individuals classified as non-cases who do not receive a diagnosis (Haney, Comer, Ward, 
Foltin, & Fischman, 1999). Positive and Negative Likelihood Ratios (LR+, LR-) are also 
produced, which are based on sensitivity and specificity and are used to assess diagnostic 
tests and calculate post-screening probabilities (Brown & Davis, 2006). Positive likelihood 
ratios (LR+) are calculated by sensitivity divided by 1 — specificity, whereas negative 
likelihood ratios (LR-) are calculated by 1 — sensitivity divided by specificity. 
Chapter 3: Results 
The sample consisted of 310 participants ranging in age from 18 years to 64 years 
(M= 27.3 years, SD= 10.3 years) of which 57% were male, 38% were female, 1% were 
transgender, and 4% did not report their gender. 27%of participants reported their highest 
level of education obtained was year 10 or below, 38% reported this as year 11 to 12; and 
34% reported their highest level of education obtained was university, of which 24% had 
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obtained a Bachelor degree and 10% had achieved higher than a Bachelor degree. In relation 
to occupational status, 43% reported being students and 37% reported that they were in paid 
employment, and 20% reported being unemployed or other (e.g., volunteer work). The mean 
age for the first time cannabis use was 17 years (range 8 to 52 years). Table 6a reports the 
base rate of DSM symptoms. Specifically, the results show that 71% reported that their 
cannabis use had caused problems with their family or friends, 32% reported that their 
cannabis use often lead to them being in unsafe situations, and 12% reported that their 
cannabis use had led them to cutting down on activities they once enjoyed, such as school or 
work. 
Table 6a 
Base rate of DSM Symptoms 
DSM Symptom 
In the past 6 months did you take more 
cannabis or a similar drug to get over or 
avoid any of these bad aftereffects? 
 
Percentage of Sample Reporting 
87% no 
13% yes 
 
In the last 6 months, did you have any of the 	 79% no 
following bad aftereffects when the effects of 21% yes 
cannabis were wearing off? This includes the 
morning after using it or in the first few days 
of stopping or cutting 
In the past 6 months have you had job or 	 91% no 
school troubles as a result of your cannabis 9% yes 
use? (e.g., missing too much work, not doing 
your work well, being demoted, or being 
suspended, or dropping out of school). 
In the past 6 months have a period when your 
cannabis use (or recovering from your 
cannabis use) often interfered with taking 
care of your home or family? 
In the past 6 months have you accidently 
injure yourself while under the influence of 
cannabis? (e.g., have a bad fall, cut yourself 
badly, hurt in a traffic accident where you 
were driving) 
91% no 
9% yes 
91% no 
9% Yes 
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During the past 6 months have you more than 	 68% no 
once drive a car, motorcycle, truck, boat, or 32% yes 
other vehicle when you were under the 
influence of cannabis? 
During the past 6 months have you found 	 81% no 
yourself under the influence of cannabis or 19% yes  
feeling its after-effects in situations that 
increased your chances of getting hurt? (e.g., 
swimming, using machinery, or walking in a 
dangerous area or around heavy traffic) 
DSM Symptom 	 Percentage of Sample Reporting 
During the past 6 months have you had 	 83% no 
arguments with your spouse, 	 17% yes 
boyfriend/girlfriend, family, or friends as a 
result of your cannabis use? 
During the past 6 months have you gotten 	 99% no 
into physical fights while under the influence 1% yes 
of cannabis? 
During the past 6 months have you continue 	 29% no  
to use cannabis even though you knew it was 71% yes 
causing you troubles with your family or 
friends? 
During the past 6 months have you tried 	 62% no 
more than once to stop or cut down using 38% yes 
cannabis but found you couldn't do it 
During the past 6 months have you often use 	 72% no 
cannabis in larger amounts or for a much 28% yes 
longer period than you meant to? 
During the past 6 months have you had a 	 80% no 
period of a month or more when you spent a 20% yes  
lot of time using cannabis or getting over its 
bad after-effects? 
During the past 6 months have you found that 	 65% no 
your usual amount of cannabis had much less 35% yes 
effect on you than it once did? 
During the past 6 months have you given up 	 88% no 
or cut down on activities that were important 12% yes 
to you in order to use cannabis like work, 
school, or associating with friends or  
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relatives?  
Note: The DSM symptom questions were mirrored in the DSM criteria questions NESARC, which included a 
series of questions that were adapted and modified from the AUDADIS-IV to create diagnostic categories. 
Of the 310 participants 54% of participants did not meet the criteria for Cannabis Use 
Disorder (DSM-5 no diagnosis), 22% met the criteria for mild Cannabis Use Disorder, 10% 
met the criteria for moderate Cannabis Use Disorder, and 14% met the criteria for severe 
Cannabis Use Disorder (see Table 6b). Additionally, according to the DSM-IV criteria 61% 
of participants did not met the criteria for cannabis dependency or abuse, 13% of participants 
met the criteria for cannabis abuse, and 26% met the criteria for cannabis dependency. 
Table 6b 
Prevalence of DSM-IV and DSM-5 Diagnosis 
DSM Diagnosis 	 Percentage of Sample Reporting 
DSM-IV Cannabis Abuse 	 30% 
DSM-IV Cannabis Dependence 	 26% 
DSM-5 Mild Cannabis Use disorder 	 22% 
DSM-5 Moderate Cannabis Use Disorder 	 10% 
DSM-5 Severe Cannabis Use Disorder 14% 
In terms of frequency of cannabis use 46% of participants reported using cannabis on 
a weekly basis (see Table 6c). Specifically, 10% of participants reported using cannabis once 
to twice a week and 36% of participants reported using cannabis three to four times a week 
on average. On a typical day when smoking cannabis, 79% of participants reported that on 
average they would smoke between 1 to 9 cones (e.g., smoking cannabis through any pipe 
instrument), bongs (e.g., strictly smoking cannabis through a water pipe), or joints and 21% 
reported smoking 10 or more cones, bongs, or joints. The most common method of smoking 
cannabis was in a joint (48%), followed by cones (23%), and bongs (18%). 
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Table 6c 
Base Rate of CUDIT-R Scale Items 
CUDIT-R Scale Item 
How often do you use cannabis? 
How many hours were you "stoned" on a 
Typical day when you had been using 
cannabis? 
How often during the past 6 months did you 
find that you were not able to stop using 
cannabis once you had started? 
How often during the past 6 months did you 
fail to do what was expected of you because 
of using cannabis? 
How often during the past 6 months have you 
devoted a great deal of time to getting, using, 
or recovering from cannabis? 
How often during the past 6 months have you 
had problems with your memory or 
concentration after using cannabis? 
How often during the past 6 months do you 
use cannabis in situations that could be 
physically hazardous, such as driving, 
operating machinery, or caring for children? 
Have you ever thought about cutting down or 
stopping your cannabis use? 
Percentage of Sample Reporting 
31% monthly or less 
22% 2 - 4 times a month 
10% 2-3 times a week 
36% 4 or more times a week 
8% < 1 hour 
29% 1 — 2 hours 
36% 3 — 4 hours 
15% 5 — 6 hours 
12%> 7 hours 
71% never 
9% < monthly 
4% monthly 
3% weekly 
13% daily or almost daily 
63% never 
22% < monthly 
7% monthly 
5% weekly 
3% daily or almost daily 
56% never 
19% < monthly 
9% monthly 
9% weekly 
8% daily or almost daily 
41% never 
28% < monthly 
12% monthly 
9% weekly 
9% daily or almost daily 
65% never 
16% < monthly 
6% monthly 
4% weekly 
9% daily or almost daily 
37% no 
22% yes 
42% unsure 
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Cannabis withdrawal was reported by 26% of participants, who reported the 
experiences of psychological, emotional, and physical symptoms two or more days after 
cannabis abstinence. Twenty-one percent of participants reported experiencing strong 
cravings for more cannabis once the initial effects had started to wear off. Tolerance was 
reported by 35% of participants and 38% reported that they have been unsuccessful in cutting 
down on their cannabis use despite wanting to. There was a significant relationship between 
the CUDIT-R and accessing services for cannabis use, r= -.33, p<.001. 
Table 7 shows the percent of other drugs (including, tobacco, alcohol, tranquilisers, 
hallucinogens/LSD/magic mushrooms, amphetamines, heroin, methadone, opioids, cocaine, 
and ecstasy) used by participants during the past six months. The most commonly used other 
drug was alcohol (91% reported use over the past six months) and followed by tobacco 
(56%). The most commonly use illicit drug was hallucinogens/LSD/magic mushrooms, with 
24% reporting use in the past six months. 
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Table 7 
Percentage of other Drugs Used in the Past Six Months 
Substance Daily or Once a week Once a Less than In the past 
almost daily or more month once a 
month 
six months 
Tobacco 26% (daily) 10% 13% (less 
than weekly) 
na 56% 
Alcohol 13% 36% 31% 20% 91% 
Tranquilisers 3% 13% 15% 69% 14% 
Hallucinogens na 2% 25% 73% 24% 
Meth/ampheta 
mines 
2% 6% 26% 66% 47% 
Heroin na 100% na na 1% 
Methadone na 10% na 90% 4% 
Opioids na 25% 19% 56% 6% 
Cocaine na na 5% 95% 7% 
Ecstasy na 6% 19% 75% 19% 
There was a significant correlation between frequency of cannabis use and age, r=.33, 
p <.001. Table 8 shows the correlations between the CUDIT-R and the total scores on the 
cannabis outcome measures and the psychosocial measures. Specifically, the CUDIT-R was 
significantly correlated with the amount of cannabis used, r= .50, p‹.001, the frequency of 
cannabis use (amount of days), r= .66, p<.001, and how many hours were spent stoned (per 
day), r= .59, p‹.001. There was a significant relationship between the CUDIT-R and the 
DSM-5 cannabis use disorder symptoms, r= .74, p<.001, the DSM-IV diagnosis of 
dependence categories, r= .57, p‹.001, the SDS r= .76, p<.001, and the K-10 r= .29, p<.001. 
There was a significant negative correlation between the CUDIT-R and SF-12, PCS r= -.22, 
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p<.001 and MCS r= -.26, p<.001 and a significant negative relationship between the CUDIT-
R and the PWI r= -.34, p<.001. 
Table 8 
Correlations between the CUDIT-R and Outcome Measures 
Scale * Correlation 
(r) 
Significance 
(13) 
Amount of cannabis used daily 299 0.50 0.001 
Frequency of cannabis use (monthly — 
weekly)* 
310 0.66 0.001 
Hours spent stoned on a typical day 
where cannabis is used 
310 0.59 0.001 
DSM-5 (total item sum) 310 0.74 0.001 
DSM-IV (total item sum) 310 0.65 0.001 
SDS (total item sum) 278 0.76 0.001 
K-10 (total score) 274 0.29 0.001 
PWI (total score) 269 -0.34 0.001 
SF-12 (physical component) (total 
score) 
266 -0.22 0.001 
SF-12 (mental component) (total 
score) 
266 -0.26 0.001 
* Participants indicated their frequency of cannabis use as one of the following: never, monthly or less, 2 -4 
times a month, 2-3 times a week, or 4 or more times a week. 
**SDS- Severity of Dependency Scale; K-10- The Kessler Psychological Distress Scale; PW1— The 
Psychological Wellbeing Inventory; SF-12 — Short Form-12 Health Survey 
***Note: The DSM variables were scored in accordance to the scoring proposed in the DSM-5 manual (e.g., 0 
to 1 criteria (no diagnosis); 2 to 3 criteria (Mild Cannabis Use Disorder); 4 to 5 criteria (Moderate Cannabis Use 
Disorder); and 6 or more criteria (Severe Cannabis Use Disorder) were created the diagnostic categories. 
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3.1: Results - DSM-IV ROC Analysis (Aim 1) 
Figure 1 illustrates the ROC curve for the CUDIT-R/DSM-IV. The AUC was 0.88, 
illustrating a roughly 88% likelihood that a randomly selected participant who was dependent 
on cannabis (according to the DSM-IV criteria) would have a higher CUDIT-R score than 
would a randomly selected participant who was not dependant on cannabis. Furthermore, the 
AUC value was significant (p<.001), and the 95% confidence interval (CI = 0.84 - 0.91) 
bounds did not include 0.50 suggesting diagnostic accuracy that was better than chance alone. 
0.00 
	
0.25 
	
0.50 
	
0.75 
	
1.00 
1- Specificity 
Figure 1. AUC Graph DSM-IV. 
The possible sensitivity and specificity scores of the CUDIT-R, ranging from 1 to 28, 
are shown in Table 9, together with the Positive Likelihood Ratio (LR+) and the Negative 
Likelihood Ratio (LR-). An optimal solution occurs with CUDIT-R scores of 13 or above 
(Youden index — 0.62), with 75% of participants with a current cannabis use disorder scoring 
at or above this level and 87% of participants without a current cannabis use disorder scoring 
below this level, correctly classifying 84% of participants. 
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Table 9 
Sensitivity, Specificity, Correctly Classified Cases, Likelihood Ratios of Positive and 
Negative Tests for the CUDIT-R in the Identification of DSM-IV Cannabis Dependence.  
CUDIT-R 
cut-off 	 Correctly 
scores 	Sensitivity 	Specificity classified 	LR+ 	LR- 	Youden 
1 1.00 0.00 0.26 1.00 0.00 
2 1.00 0.02 0.27 1.02 0.00 0.02 
3 1.00 0.10 0.33 1.11 0.00 0.10 
4 1.00 0.23 0.43 1.29 0.00 0.23 
5 1.00 0.31 0.49 1.45 0.00 0.31 
6 0.95 0.40 0.55 1.59 0.12 0.35 
7 0.93 0.50 0.61 1.83 0.15 0.42 
8 0.91 0.61 0.69 2.36 0.14 0.53 
9 0.90 0.67 0.73 2.72 0.15 0.57 
10 0.86 0.71 0.75 3.01 0.19 0.58 
11 0.79 0.77 0.78 3.48 0.27 0.56 
12 0.78 0.83 0.81 4.46 0.27 0.60 
13* 0.75 0.87 0.84 5.56 0.29 0.62 
14 0.65 0.88 0.82 5.54 0.40 0.53 
15 0.60 0.92 0.84 7.26 0.44 0.52 
16 0.55 0.94 0.84 9.73 0.48 0.49 
17 0.49 0.96 0.84 11.21 0.54 0.44 
18 0.41 0.99 0.84 31.63 0.60 0.40 
19 0.38 1.00 0.84 86.25 0.63 0.37 
20 0.31 1.00 0.82 71.87 0.69 0.31 
21 0.28 1.00 0.81 0.73 0.28 
22 0.23 1.00 0.80 0.78 0.23 
23 0.18 1.00 0.79 0.83 0.18 
24 0.15 1.00 0.78 0.85 0.15 
25 0.08 1.00 0.76 0.93 0.08 
26 0.05 1.00 0.75 0.95 0.05 
27 0.03 1.00 0.75 0.98 0.02 
28 0.01 1.00 0.75 0.99 0.01 
28 0.00 1.00 0.74 1.00 0.00 
*Optimal combination of sensitivity and specificity, based on Youden Index (sensitivity + specificity-1). 
0.50 
1 - Specificity 0.25 
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3.2: DSM-5 ROC Analysis (Aim 2) 
DSM-5 mild cannabis use disorder (met by the presence of two or more criteria) 
Figure 2 provides the ROC curve for the CUDIT-R/DSM-5 (mild). The AUC was 
0.83, roughly illustrating 83% likelihood that a randomly selected participant who had mild 
cannabis use disorder would have a higher CUDIT-R score than would a randomly selected 
participant who did not have a mild cannabis use disorder. Furthermore, the AUC value was 
significant (p<.001, 95% CI = 0.78 - 0.87) suggesting diagnostic accuracy that was better 
than chance alone. 
Figure 2. AUC Graph DSM-5 (mild). 
As in the prior analysis, sensitivity and specificity data, LR+, LR-, and Youden's 
Index values were examined to help determine the optimal cut-off scores for the DSM-5 
cannabis use dependence categories (see Table 10 - 12). An optimal solution occurs with 
CUDIT-R scores of 9 or above (Youden index — 0.53), with 76% of participants with a 
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current cannabis use disorder scoring at or above this level, and 77% of participants without a 
current cannabis use disorder scoring below this level, correctly classifying 76% of 
participants. 
Table 10 
Sensitivity, Specificity, Correctly Classified Cases, Likelihood Ratios of Positive and 
Negative Tests for the CUDIT-R in the Identification of DSM-5 (mild) Cannabis use Disorder 
CUDIT-R 
cut-off 
scores Sensitivity Specificity 
Correctly 
classified LR+ LR- Youden 
1 1.00 0.00 0.46 1.00 0.00 
2 0.99 0.02 0.47 1.02 0.29 0.02 
3 0.99 0.12 0.52 1.12 0.12 0.11 
4 0.97 0.28 0.60 1.34 0.12 0.25 
5 0.94 0.37 0.63 1.49 0.17 0.31 
6 0.87 0.47 0.66 1.66 0.27 0.35 
7 0.83 0.57 0.69 1.91 0.31 0.39 
8 0.78 0.69 0.73 2.54 0.32 0.47 
9* 0.76 0.77 0.76 3.26 0.31 0.53 
10 0.72 0.81 0.77 3.76 0.35 0.53 
11 0.64 0.86 0.75 4.43 0.42 0.49 
12 0.59 0.90 0.76 5.84 0.45 0.49 
13 0.54 0.92 0.74 6.42 0.50 0.45 
14 0.47 0.93 0.72 6.52 0.57 0.40 
15 0.42 0.96 0.71 10.01 0.61 0.38 
16 0.37 0.98 0.70 15.47 0.64 0.35 
17 0.33 0.99 0.68 27.44 0.68 0.32 
18 0.25 1.00 0.65 0.75 0.25 
19 0.22 1.00 0.64 0.78 0.22 
20 0.18 1.00 0.62 0.82 0.18 
21 0.15 1.00 0.61 0.85 0.15 
22 0.13 1.00 0.60 0.87 0.13 
23 0.10 1.00 0.58 0.90 0.10 
24 0.08 1.00 0.58 0.92 0.08 
25 0.04 1.00 0.56 0.96 0.04 
26 0.03 1.00 0.55 0.97 0.03 
27 0.01 1.00 0.55 0.99 0.01 
28 0.01 1.00 0.54 0.99 0.01 
28 0.00 1.00 0.54 1.00 00.0 
*Optimal combination of sensitivity and specificity, based on Youden Index (sensitivity + specificity-1). 
0.50 
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DSM-5 moderate cannabis use disorder (met by the presence offour or more criteria) 
Figure 3 provides the ROC curve for the CUDIT-R/DSM-5 (moderate). The AUC 
value for the ROC curve was 0.89, illustrating an approximately 89% likelihood that a 
randomly selected participant who had moderate cannabis use disorder would have a higher 
CUDIT-R score than would a randomly selected participant who did not have a moderate 
cannabis use disorder. Furthermore, the AUC value was significant (p<.001, 95% CI = 0.85 - 
0.92) suggesting diagnostic accuracy that was better than chance alone. 
Figure 3. AUC Graph DSM-5 (moderate). 
An optimal solution occurs with CUDIT-R scores of 13 or above (Youden index — 
0.61), with 76% of participants with a current cannabis use disorder scoring at or above this 
level and 85% of participants without a current cannabis use disorder scoring below this 
level, correctly classifying 83% of participants. 
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Table 11 
Sensitivity, Specificity, Correctly Classified Cases, Likelihood Ratios of Positive and 
Negative Tests for the CUDIT-R in the Identification of DSM-5 (moderate) Cannabis use 
Disorder 
CUTIT-R 
cut-off 
scores Sensitivity Specificity 
Correctly 
classified LR+ LR- Youden 
1 1.00 0.00 0.24 1.00 0.00 
2 1.00 0.02 0.25 1.02 0.00 0.02 
3 1.00 0.09 0.31 1.10 0.00 0.09 
4 1.00 0.22 0.41 1.28 0.00 0.22 
5 0.99 0.30 0.46 1.40 0.05 0.28 
6 0.96 0.40 0.53 1.59 0.10 0.36 
7 0.95 0.49 0.60 1.86 0.11 0.44 
8 0.93 0.61 0.68 2.37 0.11 0.54 
9 0.93 0.67 0.73 2.79 0.10 0.60 
10 0.89 0.71 0.75 3.05 0.15 0.60 
11 0.80 0.76 0.77 3.36 0.27 0.56 
12 0.78 0.81 0.81 4.20 0.27 0.60 
13* 0.76 0.85 0.83 5.10 0.29 0.61 
14 0.68 0.88 0.83 5.50 0.37 0.55 
15 0.64 0.92 0.85 7.49 0.40 0.55 
16 0.58 0.94 0.85 9.80 0.45 0.52 
17 0.51 0.95 0.85 11.02 0.51 0.47 
18 0.45 0.99 0.86 35.08 0.56 0.43 
19 0.41 1.00 0.85 95.68 0.60 0.40 
20 0.34 1.00 0.84 79.73 0.67 0.33 
21 0.30 1.00 0.83 0.70 0.30 
22 0.24 1.00 0.82 0.76 0.24 
23 0.19 1.00 0.81 0.81 0.19 
24 0.16 1.00 0.80 0.84 0.16 
25 0.08 1.00 0.78 0.92 0.08 
26 0.05 1.00 0.77 0.95 0.05 
27 0.03 1.00 0.77 0.97 0.03 
28 0.01 1.00 0.76 0.99 0.01 
28 0.00 1.00 0.76 1.00 0.00 
*Optimal combination of sensitivity and specificity, based on Youden Index (sensitivity + specificity-1). 
DSM-5 severe cannabis use disorder (met by the presence of six or more criteria) 
Figure 4 provides the ROC curve for the CUDIT-R/DSM-5 (severe). The AUC was 
0.90, illustrating 90% likelihood that a randomly selected participant who had severe 
0.50 
1- Specificity 
0.75 1.00 
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cannabis use disorder would have a higher CUDIT-R score than would a randomly selected 
participant who did not have a moderate cannabis use disorder. Furthermore, the AUC value 
was significant (p<.001, 95% CI = 0.85 - 0.93) suggesting diagnostic accuracy that was better 
than chance alone. 
Figure 4. AUC Graph DSM-5 (Severe). 
An optimal solution occurs with CUDIT-R scores of 13 or above (Youden index — 
64), with 84% of participants with a current cannabis use disorder scoring at or above this 
level and 80% of participants without a current cannabis use disorder scoring below this 
level, correctly classifying 80% of participants. 
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Table 12 
Sensitivity, Specificity, Correctly Classified Cases, Likelihood Ratios of Positive and 
Negative Tests for the CUDIT-R in the Identification of DSM-5 (severe) Cannabis use 
Disorder 
CUTIT-R 
cut-off 
scores Sensitivity Specificity 
Correctly 
classified LR+ LR- Youden 
1 1.00 0.00 0.14 1.00 0.00 
2 1.00 0.02 0.16 1.02 0.00 0.02 
3 1.00 0.08 0.21 1.09 0.00 0.08 
4 1.00 0.20 0.31 1.24 0.00 0.20 
5 1.00 0.27 0.37 1.36 0.00 0.27 
6 0.98 0.36 0.45 1.53 0.06 0.34 
7 0.98 0.45 0.52 1.77 0.05 0.42 
8 0.98 0.55 0.61 2.18 0.04 0.53 
9 0.98 0.61 0.66 2.48 0.04 0.58 
10 0.93 0.65 0.69 2.64 0.11 0.58 
11 0.84 0.71 0.73 2.87 0.23 0.55 
12 0.84 0.76 0.77 3.44 0.21 0.60 
13* 0.84 0.80 0.80 4.14 0.20 0.64 
14 0.73 0.82 0.81 4.12 0.33 0.55 
15 0.70 0.86 0.84 5.21 0.34 0.57 
16 0.66 0.89 0.86 6.26 0.38 0.55 
17 0.61 0.92 0.87 7.42 0.42 0.53 
18 0.57 0.96 0.90 13.74 0.45 0.53 
19 0.55 0.97 0.91 20.73 0.47 0.52 
20 0.48 0.98 0.91 25.39 0.53 0.46 
21 0.43 0.99 0.91 38.29 0.57 0.42 
22 0.34 0.99 0.90 30.23 0.67 0.33 
23 0.27 0.99 0.89 36.27 0.73 0.27 
24 0.23 0.99 0.88 30.23 0.78 0.22 
25 0.14 1.00 0.88 0.86 0.14 
26 0.09 1.00 0.87 0.91 0.09 
27 0.05 1.00 0.86 0.95 0.05 
28 0.02 1.00 0.86 0.98 0.02 
28 0.00 1.00 0.86 1.00 0.00 
*Optimal combination of sensitivity and specificity, based on Youden Index (sensitivity + specificity-1). 
Taken together these results identify that the participants involved in this study were 
low level cannabis users, with the majority identified not receiving a DSM-5 diagnosis of 
cannabis use disorder. Specifically, based on the CUDIT-R cut-off scores identified, 162/310 
(52%) of participants received a CUDIT-R score between 1-8 (no diagnosis), 57/310(18%) 
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participants received a diagnosis of mild cannabis use disorder (9-12), and 79/310 (26%) 
participants receiving a diagnosis of moderate to severe cannabis use disorder. 
SDS (cannabis outcome measure) 
Figure 5 provides the ROC curve for the CUDIT-R/SDS. The AUC value was 0.89, 
illustrating an 89% likelihood that a randomly selected participant who had higher levels of 
cannabis dependence would also score higher on the CUDIT-R than would a randomly 
selected participant who was not highly dependent on cannabis. The AUC value was 
significant (p<.001, CI = 0.85 - 0.93) suggesting diagnostic accuracy that was better than 
chance alone. 
Area under ROC curve =9.8942 
Figure 5. AUC Graph SDS 
A cut-off of 3 was identified as a optimal SDS cut-off for adults and the current 
results found an optimal solution occurs with CUDIT-R at 10 or above (Youden index — 
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0.67), with 87% of participants with higher levels of cannabis dependence scoring at or above 
this level and 80% of participants who do not have high levels of cannabis dependence 
scoring below this level, correctly classifying 82% of participants. 
Table 13 
Sensitivity, Specificity, Correctly Classified Cases, Likelihood Ratios of Positive and 
Negative Tests for the CUDIT-R in the Identification of SDS Cut-off Scores 
Cut-off 	 Correctly 
scores 	Sensitivity Specificity 	classified 	LR+ 	LR- 	Youden 
1 1.00 0.00 0.33 1.00 0.00 
2 0.99 0.02 0.34 1.01 0.51 0.01 
3 0.99 0.10 0.40 1.10 0.11 0.09 
4 0.98 0.25 0.49 1.30 0.09 0.23 
5 0.98 0.34 0.55 1.49 0.06 0.32 
6 0.95 0.46 0.62 1.76 0.12 0.41 
7 0.91 0.56 0.68 2.10 0.15 0.48 
8 0.91 0.69 0.77 2.98 0.13 0.61 
9 0.89 0.75 0.80 3.60 0.14 0.64 
10* 0.87 0.80 0.82 4.37 0.16 0.67 
11 0.75 0.85 0.82 4.98 0.29 0.60 
12 0.72 0.90 0.84 7.02 0.31 0.62 
13 0.68 0.93 0.85 9.80 0.34 0.61 
14 0.61 0.95 0.84 12.58 0.41 0.56 
15 0.54 0.97 0.83 16.85 0.47 0.51 
16 0.50 0.97 0.82 18.60 0.51 0.47 
17 0.46 0.99 0.81 42.46 0.55 0.45 
18 0.34 0.99 0.77 31.34 0.67 0.33 
19 0.29 0.99 0.76 54.59 0.71 0.29 
20 0.24 0.99 0.74 44.48 0.77 0.23 
21 0.20 0.99 0.73 36.39 0.81 0.19 
22 0.15 0.99 0.72 28.30 0.85 0.15 
23 0.12 0.99 0.71 22.24 0.89 0.11 
24 0.10 0.99 0.70 18.20 0.91 0.09 
25 0.05 1.00 0.69 0.95 0.05 
26 0.03 1.00 0.68 0.97 0.03 
27 0.01 1.00 0.67 0.99 0.01 
27 0.00 1.00 0.67 1.00 0.00 
*Optimal combination of sensitivity and specificity, based on Youden Index (sensitivity + specificity-I). 
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3.3: Result — Psychosocial Outcome Measures (Aim 3) 
For aim 2 crosstabulation analysis was used as it allows for two variables to be 
compared and reports percentages for the number of respondents in each cell of table. 
Accordingly, psychosocial outcome measure (i.e., K-10, SF-12, and PWI, variable 1) and the 
CUDIT-R cut-off scores (variable 2) were used in a crosstabulation to record the number 
(frequency) of respondents that had specific characteristics in the cells of the table. Table 14 
shows the results of the crosstabulation analysis and reports the percentages for the number of 
respondents in each cell. 
The K-10 is presented in the severity thresholds (low, mild, moderate, and severe), 
which relate to the severity of psychological distress (mental disorder experienced). As seen 
in Table 14 less than 10% of individuals who experience mild cannabis use disorder (DSM-5) 
experienced moderate-severe psychological distress (K-10) and 29% of individuals who meet 
the criteria for cannabis dependency (DSM-IV)/ moderate/severe cannabis use disorder 
(DSM-5) experienced moderate-severe psychological distress (K-10). 
As the PWI and SF-12 do not have pre-determined severity cut-off thresholds, the 
severity of symptoms was presented in terms of score below the mean. Specifically, as shown 
in Table 14 the PWI presented as one and two SD above (+1SD =87; +2SD =100) and below 
(-1SD= 63; -2SD=50) the normative values (M= 75, SD= 12.5). According to the PWI results 
less than 20% of individuals who meet the criteria for mild cannabis use disorder (DSM-5) 
experienced impaired psychological wellbeing and more than 99% who meet the criteria for 
Cannabis dependence (DSM-IV) moderate/severe cannabis use disorder (DSM-5) 
experienced impaired psychological wellbeing. 
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Table 14 displays values for the SF-12 PCS at one and two SD above (+1SD= 59; 
+25D= 69) and below (-1SD=40; -2SD= 30) the PCS normative values (M=49; SD=10). 
Table 14 also displays values for the MCS at one and two SD above (+1SD=61; +2SD= 70) 
and below (-1SD=43; -2SD= 34) the MCS normative values (M= 52; SD= 9). As seen in 
Table 14, 50% of individuals who meet the criteria for mild cannabis use disorder (DSM-5) 
will experience physical impairments (PCS) and 20% experienced mental health impairments 
(MCS). Additionally, less than 60% of individuals who meet the criteria for Cannabis 
dependence (DSM-IV) moderate/severe cannabis use disorder (DSM-5) experienced physical 
impairments (PCS) and less than 85% experienced mental health impairments. 
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Table 14 
Crosstabulation Analysis of the Psychosocial Outcome Measures and CUDIT-R Cut-off 
Scores 
Scale * 	 <9 CUDIT-R 
No diagnosis 
9-12 CUDIT-R 	>/=13 CUDIT-R 
Mild cannabis use 	Moderate-severe 
disorder (DSM-5) 	cannabis use disorder 
(DSM-5) cannabis 
dependence (DSM-
IV) 
K-10: low 72% 78% 47% 
K-10: mild 11% 16% 24% 
K-10: moderate 8% 4% 12% 
K-10: severe 9% 2% 17% 
PWI: 1SD 61% 18% 20% 
PWI: -1SD 37% 18% 45% 
PWI: 2SD 58% 18% 24% 
PWI: -2SD 23% 23% 55% 
SF-12 (physical 
component): 1SD 
54% 18% 28% 
SF-12 (physical 
component): -1SD 
29% 14% 57% 
SF-12 (physical 
component): 25D 
54% 18% 28% 
SF-12 (physical 
component): -2SD 
na na na 
SF-12 (mental 
component): 1SD 
57% 19% 25% 
SF-12 (mental 
component): -1SD 
38% 14% 48% 
SF-12 (mental 
component): 2SD 
54% 18% 28% 
SF-12 (mental 
component): -2SD 
55% 9% 36% 
*K-I0- The Kessler Psychological Distress Scale (low, mild, moderate, severe - categories of psychological 
distress); PWI — The Psychological Wellbeing Inventory (1SD and -1SD one standard deviation above and 
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below the mean, 2SD, -2SD two standard deviation above and below the mean); SF-12 — Short Form-I2 Health 
Survey (1SD and -1 SD one standard deviation above and below the mean, 2SD, -2SD two standard deviation 
above and below the mean). 
Chapter 4. Discussion 
Cannabis use and misuse are serious public health concerns worldwide (Bashford et 
al., 2010). Accordingly, cannabis screening is crucial as it enables early detection of cannabis 
use problems, which may prevent the escalation of further cannabis use and potential 
dependence (Bashford et al.). The most effective cannabis screens are identified as being 
short, easily understood by the client, simply scored by the clinician, and provide reliable 
information to the clinician to decide whether further assessment and intervention is required, 
such as the CUDIT-R (Bashford et al., 2007.). The CUDIT-R is a highly acceptable, reliable, 
and brief cannabis screener, which as the present study has found is suitable for use with both 
community and clinical populations. The current results provide valuable information 
regarding community based CUDIT-R cut-off scores based on the DSM-IV and DSM-5, as 
well as providing an indication of potential psychosocial impairments at specific severity 
thresholds (e.g., K-10; low, mild, moderate, and severe). The aim of the current study was 
first to determine CUDIT-R cut-off scores that were consistent with the DSM-IV and DSM-5 
interpretation of cannabis dependence within a community sample, which was obtained 
through ROC; and secondly, to develop a means of clinical interpretation of CUDIT-R cut-
off scores, in relation to psychological and psychosocial functioning, which was obtained 
through cross-tabulation analysis. 
For maximum utility in opportunistic cannabis screening, a screen should discriminate 
diagnostic groups along the risk continuum, from high risk (likelihood of a dependence 
diagnosis), through to non-dependent, and moderate risk of developing dependence (risky 
use), to low risk, and no risk (Bashford et al., 2010; Dawe et al., 2002). Determining the 
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severity of cannabis dependence is important to assist in developing an appropriate treatment 
response (Dawe et al.). The results of the current research identified cut-off scores, which 
discriminated thresholds along a severity of risk continuum. Specifically, a cut-off score of 
13 was the optimal criterion threshold for screening for cannabis dependence (DSM-IV) 
detecting 75% of individuals with a cannabis dependence diagnosis. A cut-off score of 9 was 
the optimal criterion threshold for screening for mild cannabis use disorder (DSM-5) 
detecting 76% of individuals with a mild cannabis use disorder diagnosis and is consistent 
with the DSM-5 diagnosis of Mild Cannabis Use Disorder (2 to 3 criteria are met). A cut-off 
score of 13 was identified for moderate-severe cannabis use disorder detecting 
76%(moderate) and 84% (severe) cannabis use disorder diagnosis (DSM-5) and is consistent 
the DSM-5 diagnosis of moderate/severe Cannabis Use Disorder (where 4 to 5 criteria are 
met). 
The cut-off score for both moderate and severe cannabis use disorder was identified 
as 13; there was no difference in the cut-off score between these two thresholds. There may 
be numerous ways of explaining perhaps the most likely is that there was not enough 
discrimination because the sample size for moderate and severe groups were potentially too 
small. The sample size may explain the uneven distribution between the threshold groups. 
For example, the severe use threshold group had a small amount of participants (n= 44), 
which may have made it less sensitive. However, the moderate category included even fewer 
participants (n= 30). Accordingly, it is unlikely that the inability for the current study to 
significantly differentiate between the moderate and severe categories was due to numbers of 
participants in each category and the sample size being too small overall. Therefore, future 
studies should look at accessing a greater sample size. 
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The results of the SDS showed a similar pattern. Specifically, a score of 10 or above 
on the CUDIT-R indicates the possibility of cannabis dependence and a cut-off score of 10 on 
the SDS is indicative of the standard adult cut-off of 3, which may also indicate possible 
cannabis dependency (note: SDS range 0-15 indicating minimum to maximum severity of 
cannabis dependence respectively). . Most participants (91%) obtained low SDS scores 
between 0 to 6 indicating that in general they had a low severity of cannabis dependence, 
with only 9% of participants scoring between 7 and 15. Again, more heavy cannabis users 
would have been beneficial in identifying high-risk categories. The SDS provides a valid 
source of concurrent validity with the CUDIT-R as both instruments are identified as 
measuring the same construct, cannabis dependence. Specifically, the SDS has a strong 
correlation with the DSM-IV (r= 0.65) and the DSM-5 (r= 0.80). 
Adamson et al. (2010) identified an optimal cut-off of 13 (being preliminary only) as 
indicating possible cannabis use disorder. Adamson et al. also reported that any score under 
13 should not be discounted as non-problematic/hazardous cannabis use, and a cut-off of 8 
was identified as indicating problematic/hazardous use, which related specifically to sub-
threshold cannabis use. The cut-off scores of 13 identified by Adamson et al. with a clinical 
treatment population is consistent with the moderate-severe cut-off score identified in the 
current research with a community population. This indicates that the same cut-off score can 
be used with community and clinical populations to indicate possible moderate-severe 
cannabis use disorder. This research has been an important first step in validating the 
CUDIT-R for use in a community setting and is the first of research in the field to achieve 
this with an Australian community sample. Additionally, a cut-off score of 13 was also 
identified for Cannabis Dependency (DSM-IV). Therefore, there is no difference in cut-off 
scores between community and clinical population on the CUDIT-R when using DSM-IV 
criteria. 
However, the sub-threshold cut-off score identified by Adamson et al. of 8 indicating 
problematic/hazardous cannabis use is inconsistent with the current research, which found 9 
to be an optimal cut-off for mild cannabis use disorder. Accordingly, different cut-off scores 
are identified for community and clinical populations at mild cannabis use or 
problematic/hazardous cannabis use. This may be explained in one of two ways. Firstly, 
clinical and community populations may differ in severity at lower levels of cannabis use. 
Specifically, it may be the case that clinical population experience greater problems with low 
level cannabis use than community samples, which is accounted for by a lower cut-off score. 
Alternatively, the difference in cut-off scores between the community and clinical 
populations may be a result not in the samples, but differences between the DSM-IV and 
DSM-5, specifically regarding the DSM-5 being more sensitive and identifying sub-threshold 
'diagnostic orphans'. Moreover, if the DSM-5 was used to identify cut-off scores on the 
CUDIT-R with a clinical sample as opposed to the DSM-IV, the cut-off of 8 may change to 
reflect the changes made between manuals. However, this remains unclear and an area for 
future research. 
Comparisons with other reports of cannabis use in Australia are difficult. However, 
the prevalence estimates of dependence in the current study compare well with other 
Australian and New Zealand estimates (Anthony, Warner, & Kessler, 1994; Fergusson & 
Horwood, 1997; Coffey, Carlin, Degenhard, Lynske, Sanci, & Patton, 2002). Specifically, in 
the current study high frequency of symptoms reflected compulsive or an inability to cut 
down on cannabis use, with almost one third of participants reporting a persisting desire to 
use cannabis. Moreover, continued use despite knowledge of cannabis use causing physical 
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and/or psychological problems was endorsed by almost one third of participants. Unlike other 
studies (Coffey et al., 2002) that have found tolerance to be far less common than withdrawal 
amongst cannabis users, the current research indicated that the experience of tolerance 
exceeded the experience of withdrawal, with over one third of participants endorsing the 
experience of tolerance to cannabis. This may possibly be explained by the sample. For 
example, Coffey et al's sample consisted of only young Australian adults (M=21 years old, 
range 20 to 21 years old), whereas the current sample consisted of a wider age range (M=27 
years old, range 18 to 64 years old). 
The Psychosocial Outcome Measures 
It is important to understand the psychosocial impacts of cannabis use in order to 
better understand the function and target of intervention to manage and prevent escalation of 
further dependence (Copeland et al., 2001). The psychosocial outcome measures used in the 
current research assisted in identifying possible psychosocial impairments at specific CUDIT-
R severity threshold, which can be used by healthcare workers to draw inferences about 
possible psychosocial impairments the user may currently be experiencing. these statistics 
provide an indication of the potential percentage of people who will experience impairments 
in specific areas of psychosocial functioning across the CUDIT-R cut-off scores. This is 
important information as it can guide healthcare professionals as to what psychosocial 
impacts may be expected at different levels of cannabis dependence, as well as informing the 
development of interventions aimed at better management and providing healthcare workers 
with some insight into the user's functioning. 
The current research was consistent with previous research (Coffey et al., 2001; 
Coscone, Zimmermann, Auckenthaler, & Robert-Tissot, 2011) that has focused on the 
psychosocial impacts of cannabis use. Overall the current research identified that individuals 
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who are dependent on cannabis may have a wide-range of additional psychosocial problems, 
such as: emotional and psychological distress, which increase with moderate — severe 
cannabis use dependence; physical and mental health impairments, which are more impaired 
with the high cannabis use severity; and impaired wellbeing in autonomy, environmental 
mastery, personal growth, positive relations with others, purpose in life, and self-acceptance 
with higher levels of cannabis severity. The K-10, SF-12, and the PWI percentages should be 
used as a guide as to the percentage of people who may experience these impacts across the 
severity thresholds. 
Table 15 shows an interpretation of the psychosocial outcome measures at CUDIT-R 
severity thresholds. Specifically, individuals who score 9 or below (no diagnosis) on the 
CUDIT-R are likely to experience/report no to mild impairments on their psychosocial 
functioning. However, the level of impairment will depend on population norms and should 
be assessed in accordance to this. Simple advice about cannabis use should be provided. 
Individuals who obtain a CUDIT-R score between 9-12 (mild cannabis use disorder) are 
likely to observe greater psychosocial impairments. For example, approximately 10% of 
cannabis users reported experiencing moderate — severe psychological distress, 
approximately 20% of individuals experienced impaired psychological wellbeing, 50% 
reported physical health impairments, and approximately 20% reported experiencing mental 
health impairments. Accordingly individuals who obtain a CUDIT-R of 9-12 should be 
provided with simple advice, brief substance use intervention, and regular monitoring. 
Finally, individuals who score 13 and above on the CUDIT-R, which refers to 
cannabis dependence in the DSM-IV and moderate/severe cannabis use disorder in the DSM-
5, are likely to experience the greatest impairments to their psychosocial wellbeing. 
Specifically, approximately 30% of individuals who obtained a CUDIT-R score of 13 also 
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reported experiencing moderate to severe psychological distress, almost all individuals who 
obtained this score also reported impairments to psychological wellbeing (99%), 
approximately 60% reported physical impairments, and approximately 85% reported mental 
health impairments. Accordingly, for people who obtain a CUDIT-R score of 13 or above 
further treatment and evaluation is recommended. 
The psychosocial results are beneficial as they help provide an indication of the 
amount of individuals who may experience different forms of psychosocial impairments at 
different CUDIT-R severity cut-off points. This information can be used to better understand 
possible impairments at each severity level and tailor interventions to prevent further 
dependence. 
Table 15 
Interpretation of the CUDIT-R Cut-Off Scores 
CUDIT-R score Severity threshold 
	
Psychosocial outcomes and 
recommendations 
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<9 	 No diagnosis 
13+ 	 Cannabis 
dependence (DSM-
IV) moderate/severe 
cannabis use 
disorder (DSM-5) 
Mainly with population norms 
Simple advice 
<10% moderate-severe psychological 
distress (K-10) 
<20% impaired psychological wellbeing 
(PWI) 
50% physical impairments (PCS) 
23% mental health impairments (MCS) 
Simple advice and brief intervention and 
monitoring 
29% moderate-severe psychological 
distress 
>99% impaired psychological wellbeing 
(PWI) 
<60% physical impairments (PCS) 
<85% mental health impairments (MCS) 
Further evaluation and treatment 
9-12 
	
Mild cannabis use 
disorder (DSM-5) 
In addition to the psychosocial measures of impaired functioning, the results obtained 
from the DSM-IV and DSM-5 in the current research also indicated that over half of the 
participants reported that their cannabis use had caused problems with their family or friends, 
had often lead to them being in unsafe situations, and had led to them cutting down on 
activities they once enjoyed such as school or work. These results are consistent with those 
identified by Coffey et al. (2002), who identified that cannabis dependence was associated 
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with social impairments, including difficulties with interpersonal relationships and 
maintaining motivation and interest in social activities. 
Similar results were also reported by Cascone, Zimmermann, Auckenthaler, and 
Robert-Tissot (2011) in their research with a young Swiss adult population. Cascone et al. 
identified that the interpersonal difficulties with peers, school, and family need to be dealt 
with first in order to be able to influence cannabis-using behaviours. Accordingly, the current 
results provide invaluable information regarding the psychosocial difficulties associated with 
cannabis dependence. Therefore, practical interventions may be based around the knowledge 
of such impairments to enhance health and wellbeing. For example, psychosocial 
interventions may focus on interpersonal relationships and communication as an intervention 
to enhance individual's socialisation and social experiences prior to targeting the 
management of the cannabis use. 
Methodological Limitations 
The current results provide important information regarding CUDIT-R cut-off scores 
for cannabis use problems and possible psychosocial impairments at these cut-offs. 
However, the study is not without its limitations, which must be kept in mind when 
interpreting the results of the study. The current study had a good representation of 
participants across location and across age groups and obtained a larger sample size than both 
Adamson et al's. (2010) and Gossop et al. (1995). However, additional participants would 
have been beneficial to gain larger numbers in the psychosocial categories. Specifically, there 
was insufficient data in the SF-12 (physical component) -2SD category, and accordingly no 
data was produced for this category. Greater numbers in the psychosocial outcome measures 
may have influenced the results and may have provided data for each psychosocial outcome. 
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category. Additionally, the majority of the participants were university students and identified 
as low-level cannabis users. Specifically, 54% of the current participants reported monthly 
use (1 to 4 times), or less than monthly use, while the rest 46% were using cannabis 1 to 4 or 
more times a week over the past 6 months. Accordingly, the data included a relatively small 
sample of high-risk cannabis users. 
Another limitation was that although the online survey design employed in this 
research allowed for greater accessibility in a more time efficacy and less intrusive manner, it 
also resulted in incomplete survey, where the participants had either saved and not returned to 
the survey or dropped out half way through the survey. Additionally, as the data was based 
on self-report, it may have been subject to associated sources of bias, such as hesitancy to 
disclose information about illicit drug (cannabis) use (Bashford et al., 2010; Cheung et al., 
2010). Accordingly, the use of online self-reports to diagnoses dependence was a potential 
limitation with the current study. 
Directions for Future Research 
There are often fundamental pitfalls in the use of psychometric instruments, which are 
sometimes overlooked in the clinical research literature (Hammond, 1995), One such 
problem has emerged with the CUDIT-R in terms of different item functioning across 
populations. The current study identified CUDIT-R community based cut-off scores for the 
DSM-IV, DSM-5, and a percentage of people who may experience possible psychosocial 
impairments at different CUDIT-R cut-off scores. However, research to date using the 
CUDIT-R is still largely based on psychometric data from clinical populations, which has 
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been obtained mostly from inpatient psychiatric populations and generalised to non-clinical 
populations. 
As a result it is assumed that different populations, namely clinical populations and 
non-clinical populations, perform the same on the CUDIT-R. Accordingly, it is important to 
examine whether or not the likelihood of item (category) endorsement is equal across 
populations (Teresi et al., 2009). This is a major limitation of the CUDIT-R as there may be 
underlying differences on item endorsement between the populations, which are not being 
account for. If this is the case, this may have serious implications for the scoring and 
interpretation of CUDIT-R scores depending on the population being screened. Accordingly, 
this is an important area for future research. Additionally, additional research focusing on the 
psychosocial outcome measures may be beneficial is gaining more specific intervention. 
Moreover, further analysis, such as performing a chi-square analysis following the 
crosstabulation analysis would expand on the existing results and be of great benefit for 
future research. 
Conclusions 
Cannabis use is adversely impacting the health and social functioning of a larger and 
expanding cohort of adults and youth around the world (Bashford et al., 2010). Targeted, 
routine, and opportunistic screening with early intervention for cannabis problems has the 
potential for enormous gains in public health. The aims of the current study was to determine 
CUDIT-R cut-off scores that were consistent with the DSM-IV and DSM-5 interpretation of 
cannabis dependence within a community sample and to develop a means of clinical 
interpretation of CUDIT-R cut-off scores in relation to psychological and psychosocial 
functioning. The cut-off scores identified in the current study can be used by allied health 
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professionals to better identify levels of cannabis use severity, which may inform tailored 
interventions aimed at reducing the trajectory of further dependence. According to Bashford 
et al. the hallmark of a cannabis screener for early intervention incudes one that is reliable, 
time-efficient, and is in accordance with a valid classification of a broad range of cannabis 
related harms and problems; the CUDIT-R satisfies these criteria. 
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Appendix Al: Advertising Poster 
-lave you used cannabis in the past six months? If so 
you could WIN 1 of 3 $500 JB HIFI vouchers! 
Jniversity of Tasmania researchers are looking for people to 
complete an anonymous online survey on the positive and 
egative effects of smoking cannabis and their general health 
and wellbeing. 
'you are over the age 
• 18 and have used 
Lnnabis in the past 6 
ionths then you can 
anplete the anonymous 
Iline survey and enter 
te prize draw to 
VIN 1 of 3 $500  
B HIFI  
ouchers!!  
Co find out more head to: 
vww. goo.gl/MRmNJ (the full like is below) 
Jr email us at: 
:uditstudy 2011@yahoo.com.au  
his study has been approved by the Tasmania Social Sciences Human Research Ethics Committee H0012077. 
you'd like to talk to someone about your cannabis use, try the cannabis information helpline on 180 30 40 50, 
rhich is a free call nationally. The full web address for the study is 
ttps://suryeys.psychol.utas.edu.au/index.php?sid=75648 
Appendix A2: Invitation used on Forums and Facebook 
Have you used cannabis in the past 6 months? 
Are you over the age of 18 years old? 
Do you want the opportunity to WIN 1 of 3 $500 JB HiFi vouchers? 
University of Tasmania researchers are looking for people who have used cannabis to 
complete an anonymous online survey. The survey takes approximately 40 minutes to 
complete and asks about the positive and negative effects of smoking cannabis and your 
general health and wellbeing. To find out more, head to this link: www. goo.gl/MRmNJ   or 
email the researchers at: cuditstudy 2011@yahoo.com.au . 
82 
83 
Appendix A3: Letters Inviting Australian Universities to Participate 
To whom it may concern, 
Requesting Assistance Advertising Psychological Research 
My name is Sophie Marshall and I am a Master of Psychology (Clinical) student at the 
University of Tasmania. I am writing to request your assistance with advertising our research 
on your campus in order to support us in recruiting a comprehensive sample of cannabis users 
in Australia. 
Under the supervision of Dr. Raimondo Bruno (UTAS) and Dr. Simon Adamson (National 
Addiction Centre, New Zealand), my research project aims to develop clinical cut-off scores 
to aid in the interpretation of the Cannabis Use Identification Test — Revised (CUDIT-R), a 
brief screening tool for cannabis use problems that has applications in both primary medical 
care and psychological services. The study is designed to develop indicative cut-off scores 
(no dependency, mild dependency, moderate dependency, and severe dependency) that are 
consistent with the DSM-IV and DSM-5 definitions of cannabis dependency in a community 
sample. In addition, the study also aims to develop a means of clinical interpretation of these 
cut-off scores, in relation to psychological and psychosocial functioning and possible clinical 
intervention where required. To achieve this we have developed a 30-minute anonymous 
online survey, which along with the CUDIT-R, includes several standardised scales. 
The study is open to all individuals over the age of 18, living in Australia, and who have 
smoked cannabis in the past six months. 
I hope that you will consider my request and assist us with advertising our research. We have 
enclosed several copies of a promotional poster and would greatly appreciate it if you 
could place these on relevant bulletin boards in your school. 
For your information I have included the information sheet and recruitment poster with this 
letter. If you have any further questions in relation to this project please contact me at 
sophiem2@utas.edu.au or on 04262264956 to discuss how to proceed. 
Thank you for your time, 
Sophie Marshall I Provisional Psychologist 
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Appendix A4: Press Media Advertisement (wrap add) 
 
CANNABIS 
RESEARCH 
 
University of Tasmania researchers 
are looking for people to participate in 
confidential research on the effects of cannabis. 
  
Do you regularly (0 
use cannabis? 
  
0 Have you used cannabis 
in the past 6 months? 
   
   
    
     
     
	) You could win 1 of 3 $500 
JB HIFI vouchers by 
completing an anonymous 
online survey about your 
use, health and wellbeing. 
Have you previously used (C) 
cannabis regularly? 
$40 reimbursement is 
available for a 2 hr study 
of brain function 
To find out more head to: 
goo.gl/MRmNJ or email: 
cuditstudy_2011@yahoo.com.au 
For more info: 
Call 0477 411 151 or 
cannabisattention@gmail.com  
Tasmania Human Research Ethics Committee Approval refs: 
H001 2077/H0009396. 
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Appendix B: Full Online Questionnaire 
1 [CR_Age] 
How old are you? Please enter your age in years. 
* 
Please write your answer here: 
268. 
2 [CR_Iive] 
Do you live in Australia? 
* 
Only answer this question if the following conditions are met: 
Please choose only one of the following: 
A. 0 Yes 
B. ONo 
3 ICR_sixmonths] 
Have you used any cannabis over the past six months? 
* 
Only answer this question if the following conditions are met: 
Please choose only one of the following: 
• 0 Yes 
• 0 No 
4 [CR_exit]Thankyou for your interest in this research. This study is being conducted in 
partial fulfillment of a Masters degree for Sophie Marshall under the supervision of Dr. 
Raimondo Bruno at the University of Tasmania. Unfortunately you are not eligible to 
participate in this study because either: 
• You are not over the age of 18 years old; 
• Do not live in Australia; or 
• have not smoked cannabis in the past 6 months. 
Please contact the researchers by email cuditstudy 2011@yahoo.com.au  if you would 
like more information. 
Only answer this question if the following conditions are met: 
DG 
5 [gender] What is your gender? 	 _ 
Please choose the appropriate response for each item: 
Male 	 Female 	Tran6nder 
0 0 
6 [language] Do you speak another language other than English? 
Please choose only one of the following: 
• 0 Yes 
• 0 No 
7 [living] What state or territory do you currently live in? 
Please choose only one of the following: 
• 0 Tasmania 
• 0 Victoria 
• 0 New South Wales 
• 0 Queensland 
• 0 Western Australia 
• 0 South Australia 
• 0 Australian Capital Territory 
• 0 Northern Territory 
8 [school]Are you still in school? 
Please choose only one of the following: 
• 0 Yes 
• 0 No 
9 [grade] What grade are you in? 
Only answer this question if the following conditions are met: 
Please write your answer here: 
10 [edu] What is the highest level of education you have completed? 
Please choose only one of the following: 
• 0 I did not go to school 
• 0 Primary 
• 0 Secondary 
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• 0 Highschool 
• 0 College 
• 0 University 
11 [education] What is the highest qualification that you have completed? 
Please choose only one of the following: 
• 0 Trade-certificate 
• 0 Non-trade certificate 
• 0 Associate diploma 
• 0 Bachelor degree 
• 0 Higher than a bachelor degree 
• 0 None 
12 [employment] Which of the following best describes your current employment 
status? 
Please choose only one of the following: 
• 0 Self-employed 
• 0 Employed for wages or payments 
• 0 Unemployed 
• 0 Looking for work 
• 0 Solely engaged in home duties 
• 0 A student 
• 0 Retired or a pension 
• 0 Volunteer or charity work 
• 0 Unable to work 
• 0 Other 
13 [workcapacity] If you work, which best describes your work capacity? 
Only answer this question if the following conditions are met: 
Please choose the appropriate response for each item: 
Full time or Part time employment 
Which best describes your work capacity? 
CUDIT-R 
14 Ifrequency]How often do you use cannabis? * 
Please choose only one of the following: 
• 0 Never 
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• 0 Monthly or less 
• 0 2 to 4 times a month 
• 0 2 to 3 times a week 
• 0 4 or more times a week 
15 [stoned] How many hours were you "stoned" on a typical day when you had been 
using cannabis? * 
Please choose only one of the following: 
• 0 Less than 1 
• 0 1 or 2 
• 0 3 or 4 
• 0 5 or 6 
• 0 7 or more 
16 [cannabis]How often during the past 6 months... 
Please choose the appropriate response for each item: 
...did you find that you were not able to stop using cannabis once you had started? 
...did you fail to do what was normally expected from you because of using cannabis? 
...have you devoted a great deal of your time to getting, using, or recovering from cannabis? 
...have you had a problem with your memory or concentration after using cannabis? 
How often do you use cannabis in situations that could be physically hazardous, 
such as driving, operating machinery, or caring for children? 
17 [cutting down] Have you ever thought about cutting down, or stopping, your use of 
cannabis? * 
Please choose only one of the following: 
• 0 Never 
• 0 Yes, but not in the past 6 months 
• 0 Yes, during the past 6 months 
FOCU 
18 Ifrequency_agel 
How old were you when you the first time you used cannabis? 
Please enter your age in years. 
Please write your answer here: 
• 
19 [frequency_intake]What is your preferred method of cannabis intake? 
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Please choose only one of the following: 
• 0 Joint 
• 0 Bong 
• 0 Dry pipe 
• 0 Vaporiser 
• 0 Eat (e.g., cookies) 
• 0 Bucket 
• 0 Other 
20 [20c] 
In the last 6 months have you used any synthetic cannabinoids (like Kronic, Spice, 
Karma, Voodoo, .INVH)? 
Please choose only one of the following: 
• 0 Yes 
• 0 No 
21 [20(11110w often have you had synthetic cannabinoids in the last 6 months? 
Only answer this question if the following conditions are met: 
Please choose only one of the following: 
• 0 Just once or twice 
• 0 Every few months 
• 0 About once a month 
• 0 Once a week or more 
• 0 Every day 
22 Ifrequency_amount] On a typical day when you use cannabis, on average, how many 
cones, bongs, or joints do you normally have? 
Please write your answer here: 
• 
Please put the number of cones, bongs, or joints that you have per day on average (e.g., 
if you smoke 10 bongs, put "10" in the box provided, without the quotation marks) 
23 [20alfor your previous answer, were you counting the number of... 
Please choose only one of the following: 
• 0 Cones 
• 0 Bongs 
• 0 Joints 
• 0 Other 
24 120b1Recently, about how many cones would you get from 1 gram of cannabis? 
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Only answer this question if the following conditions are met: 
Please write your answer here: 
25 Ifrequency_received] Please indicate how you have typically accessed cannabis over 
the past 6 months. 
Please choose only one of the following: 
• 0 Purchased it from a friend 
• 0 Paid for it from a dealer/supplier 
• 0 Have been given it 
• 0 Have own supply 
• 0 Other 
26 Ifrequency_pay] If you pay for cannabis, how much have you spent over the past 4 
weeks on cannabis? 
Only answer this question if the following conditions are met: 
Please choose only one of the following: 
• 0 $0 
• 0$25 
• 0 $25-$50 
• 0$50 -$100 
• 0$100-$150 
• 0$150-$200 
• 0 $200-$300 
• 0 More than $300 
27 Ifrequency_6mnths]How has cannabis affected your finances in the last 6 months? 
Please choose the appropriate response for each item: 
In the past 6 months, have you spent money that was meant for other things (e.g., rent) on cannabis ? 
In the past 6 months, have you sold any of your belongings to buy cannabis? 
Do you have any drug realted debts? 
Do you find yourself making excuses about money? 
Have you found yourself worried about the amount of money you spend on carmabis? 
28 [frequency_services] Have you ever accessed services (e.g., General Practitioner or 
drug services) for your cannabis use? 
Please choose only one of the following: 
• 0 Yes 
• 0 No 
29 [frequency_treatment] if Yes, what is the main type of drug treatment you are 
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currently in? 
Only answer this question if the following conditions are met: 
Please choose only one of the following: 
• 0 Not in treatment currently 
• 0 Residential rehabilitation 
• 0 Therapeutic community 
• 0 Narcotics Anonymous 
• 0 Drug counselling 
• 0 Internet services (e.g., online counselling or forums) 
• 0 Other 
30 Ifrequency_treatforms]What forms of treatment have you been in over the last 6 
months? 
Only answer this question if the following conditions are met: 
Please choose all that apply: 
• LI Haven't been in treatment in the last 6 months 
• El Residential rehabilitation 
• El Therapeutic community 
• El I Narcotics anonymous 
• El Drug counselling 
• El Internet services (e.g., online counselling or forums) 
• ElOther: 
DV 
31 IDSM-VIThe following questions are asking about your cannabis use over the past 6 
months. In the last 6 months, did you.... 
Please choose the appropriate response for each item: 
...have job or school troubles as a result of your cannabis use? (e.g. missing too much work, not doing 
your work well, being demoted, or being suspended, or dropping out of school) 
...have a period when your cannabis use (or recovering from your cannabis use) often interfered with 
taking care of your home or family? 
•..accidently injure yourself while under the influence of cannabis? (e.g. have a bad fall, cut yourself badl: 
hurt in a traffic accident where you were driving) 
...more than once drive a car, motorcycle, truck, boat, or other vehicle when you were 
under the influence of cannabis? 
...find yourself under the influence of cannabis or feeling its after-effects in situations 
that increased your chances of getting hurt? (e.g. swimming, using machinery, or 
walking in a dangerous area or around heavy traffic) 
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...get arrested, held at a police station or have any other legal problems because of cannabis use? 
...have arguments with your spouse, boyfriend/girlfriend, family, or friends as a result of your cannabis 
use? 
...get into physical fights while under the influence of cannabis? 
32 [ABu21 
Only answer this question if the following conditions are met: 
Please choose the appropriate response for each item: 
...continue to use cannabis even though you knew it was causing you troubles with your family or 
friends? 
33 IDSMV21/n the last 6 months, did you.... 
Please choose the appropriate response for each item: 
Yes 	No 
...more than once want to stop or cut down on using cannabis? 
34 [DSM-V31 
Only answer this question if the following conditions are met: 
Please choose the appropriate response for each item: 
...more than once try to stop or cut down using cannabis but found you couldn't do it? 
35 [DSMV4]The following questions are asking about your cannabis use over the past 6 
months. In the last 6 months, did you.... 
Please choose the appropriate response for each item: 
...often use cannabis in larger amounts or for a much longer period than you meant to? 
...have a period of a month or more when you spent a lot of time using cannabis or 
getting over its bad after-effects? 
...have a period of a month or more when you spent a lot of time making sure you 
always had enough cannabis available? 
...find that your usual amount of cannabis had much less effect on you than it once did? 
...find that you had to use much more cannabis than you once did to get the effect you wanted? 
...give up or cut down on activities that were important to you in order to use cannabis 
like work, school, or associating with friends or relatives? 
...give up or cut down on activities that you were interested in or that gave you 
pleasure in order to use cannabis? 
36 IDSMV51 
Only answer this question if the following conditions are met: 
Please choose the appropriate response for each item: 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
  
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
 'D< 
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Yes 	No 
)id this (giving up on activities) happen 3 or more times for a month or more? 
	
0 	0 
37 IDSMV61/n the last 6 months, did you.... 
Please choose the appropriate response for each item: 
...continue to use cannabis even though it was making you feel depressed, 
uninterested in things, or suspicious and distrustful of other people? 
...continue to use cannabis even though you knew it was causing you a health problem 
or making a health problem worse? 
38 IDSMV71/n the last 6 months, did you have any of the following bad aftereffects wizen 
the effects of cannabis were wearing off? This includes the morning after using it or in 
the first few days of stopping or cutting down on it. Did you.... 
Please choose the appropriate response for each item: 
...feel depressed? 
..•feel yourself sweating or your heart beating fast? 
...have the chills? 
...have a fever? 
...feel anxious or nervous? 
...have stomach aches, cramps or diarrhoea? 
...become so restless you fidgeted, paced or couldn't sit still? 
...find youself sweating, your pupils dilating or your hear standing up? 
..•have trouble falling asleep or staying asleep? 
...have bursts of anger or being aggressive? 
...find yourself shaking? 
...have very bad headaches? 
...becomre irritated more easily than usual? 
...eat less than usual or lose weight? 
...have a strong craving for more cannabis? 
39 IDSM81/n the last 6 months... 
Only answer this question if the following conditions are met: ° 
Please choose the appropriate response for each item: 
...was there ever a time where two or more of these problems occurred together for two days or more 
because of stopping, cuttign down on, or going without cannabis? 
40 [DSM9]/n the last 6 months, did you.... 
Please choose the appropriate response for each item: 
...take more cannabis or a similar drug to get over or avoid any of these bad aftereffects? 
CEQ 
41 [expectancy] 
The following questions ask about what impact cannabis has on you. Please indicate 
how true each statement is for you. 
Please choose the appropriate response for each item: 
I get better ideas when smoking cannabis 
Little things annoy me less when I am smoking cannabis 
I am more worried about what others are saying about me when I am smoking cannabis 
Smoking cannabis makes me feel outgoing and friendly 
Smoking cannabis makes me feel tense 
I have more self-confidence when smoking cannabis 
I have bizarre or strange thoughts when smoking cannabis 
I smoke cannabis to get full enjoyment out of life 
Smoking cannabis makes me more sexually responsive 
Smoking cannabis makes me confused 
I am more aware of what I say and do when I am smoking cannabis 
I feel restless when smoking cannabis 
I am more depressed when smoking cannabis 
Smoking cannabis makes me feel sluggish 
When I smoke cannabis I withdraw from others 
When I smoke cannabis it is easier to express my feelings 
Smoking cannabis increases my tension 
When I smoke cannabis I find it hard to get certain thoughts out of my head 
When I smoke cannabis I feel less motivated 
Smoking cannabis makes me laugh 
I tend to adopt a "who cares" attitude when smoking cannabis 
Smoking cannabis makes me more easily irritated 
I feel less shy if I have been smoking cannabis 
Smoking cannabis helps me to feel "normal" again 
When I smoke cannabis my mood feels flat 
Smoking cannabis makes me happy 
Smoking cannabis helps me concentrate 
When I am smoking cannabis I avoid people or situations for fear of embarrassment 
When I smoke cannabis I can speak my mind 
I am disappointed in myself when smoking cannabis 
I tend to avoid sex if I have been smoking cannabis 
I am clumsier when smoking cannabis 
Cannabis helps me to get along with others 
Smoking cannabis makes me feel insecure 
When smoking cannabis I do things that I do not really mean to do 
I have more energy when smoking cannabis 
I lose most feelings of sexual interest after I have been smoking cannabis 
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Cannabis makes me feel more jumpy and agitated 
When I smoke cannabis I feel "panicky" 
Smoking cannabis makes me feel excited 
When smoking cannabis I have thoughts that are not my own 
When smoking cannabis my feelings rapidly shift from one to another 
Smoking cannabis gives me more energy 
When smoking cannabis people find it difficult to understand me 
When smoking cannabis I feel out of touch with reality 
SDS 
42 [Severity concerned]In the last 6 months... 
Please choose the appropriate response for each item: 
Did you ever think your use of cannabis was out of control? 
Did the prospect of missing a smoke make you very anxious or worried? 
Did you worry about your use of cannabis? 
Do you wish you could stop using cannabis? 
43 [Severity_stopping] How difficult would you find it to stop or to go without 
cannabis? 
Please choose only one of the following: 
• 0 Not difficult 
• 0 Quite difficult 
• 0 Very difficult 
• 0 Impossible 
K-10 
44 Ili-101 Please indicate what best represents how you have been over the past 
month. During the last month, about how often did you.... 
Please choose the appropriate response for each item: 
...feel tired out for no good reason? 
...feel nervous? 
...feel so nervous that nothing could calm you down? 
...feel hopeless? 
•..feel restless or fidgety? 
... feel so restless you could not sit still? 
...feel depressed? 
...feel that everything was an effort? 
...feel so sad that nothing could cheer you up? 
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...feel worthless? 
45 IMHQCIThe following questions ask about things in the last 6 months 
Please choose the appropriate response for each item: 
Have you ever had any mental health problems in the last 6 months, such as 
depression, anxiety, or psychosis? This includes any issues that you haven't spoken 
to a health professional about. 
Have you attended an appointment with a health professional for mental health 
problems in the last 6 months? 
Have you been prescribed any medication for a mental health problem in the past 6 
months? 
46 IMHDX]What was this mental health problem (or problems)? 
Only answer this question if the following conditions are met: 
Please choose all that apply: 
• 111 Depression 
• LI Anxiety or panic 
• 111 Schizophrenia 
• El Post-traumatic stress disorder 
• 00ther: 
SF-12 
47 ISF_health] In general would you say your health is: 
Please choose only one of the following: 
• 0 Excellent 
• 0 Very good 
• 0 Good 
• 0 Fair 
• 0 Poor 
48 [SF activities]The following questions are about activities you might do during a 
typical day. Does your health now limit you in these activities? If so, how much? 
Please choose the appropriate response for each item: 
Moderate activities, such as moving a table, pushing a vacuum cleaner, bowling, or 
playing golf or climbing several flights of stair. 
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49 [SF_6mnths]During the past 4 weeks, have you had any of the following problems 
with your work or other regular daily activities as a result of your physical health? 
Please choose the appropriate response for each item: 
Yes 	No 
Accomplished less than you would like 
Were limited in the kind of work or other activities 
	
00 
50 [SF_4emot]During the past 4 weeks, have you had any of the following problems 
Not at all 	A little bit 	Moderately 	Quite a bit 	Extremely 
with your work or other regular daily activities as a result of any emotional problems 
(such as feeling depressed or anxious)? 
Please choose the appropriate response for each item: 
Yes 	No 
Accomplished less than you would like 
	 00 
Did work or other activities less carefully than usual 
	00 
51 [SF _houswork]During the past 4 weeks, how much did pain interfere with your 
normal work (including both work outside the home and housework)? 
Please choose the appropriate response for each item: 
52 [SF_outcomes] 
These questions are about how you feel and how things have been with you during the 
past 4 weeks. For each question, please give the one answer that comes closest to the 
way you have been feeling. 
How much of the time during the past 4 weeks... 
Please choose the appropriate response for each item: 
Have you felt calm and peaceful? 
Did you have a lot of energy? 
Have you felt downhearted and blue? 
53 ISFlast]During the past 4 weeks, how much of the time has your physical health or 
emotional problems interfered with your social activities (like visiting friends, relatives, 
etc.)? 
Please choose the appropriate response for each item: 
NHHS 
54 [alcohol] 
The following questions are interested in your experience with drugs other than 
cannabis in the last six months 
How often do you have a drink containing alcohol? 
Please choose only one of the following: 
• 0 Never 
• 0 Monthly or less 
• 0 2 to 4 times a month 
• 0 2 to 3 times a week 
• 0 4 or more times a week 
55 Ialcohol_howmany] How many standard drinks do you have on a typical day when 
you are drinking? 
Only answer this question if the following conditions are met: 
Please choose only one of the following: 
• 0 1 or 2 
• 0 3 or 4 
• 0 5 or 6 
• 0 7 to 9 
• 0 10 or more 
56 [alcohol six-I-glow often do you have six or more standard drinks on one occasion? 
Only answer this question if the following conditions are met: 
Please choose only one of the following: 
• 0 Never 
• 0 Less than monthly 
• 0 Monthly 
• 0 Weekly 
• 0 Daily or almost daily 
57 RobaccolDo you smoke tobacco? (this includes tobacco mixed in with cannabis) 
Please choose only one of the following: 
• 0 Yes 
• 0 No 
58 [tobac2]How often did you smoke tobacco? 
Only answer this question if the following conditions are met: 
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Please choose only one of the following: 
• 0 Daily 
• 0 At least weekly (but not daily) 
• 0 Less often than weekly 
59 Itranquillisers]Have you used tranquillisers and/or sleeping pills (e.g. benzos, valium, 
alprazolam, temazepam) for non-medical purposes in the last 6 months? 
Please choose only one of the following: 
• 0 Yes 
• 0 No 
60 [tranquilisers_howoft]In the last 6 months, how often did you use 
tranquilisers/sleeping pills for non-medical purposes? 
Only answer this question if the following conditions are met: 
Please choose only one of the following: 
• 0 Every day 
• 0 Once a week or more 
• 0 About once a month 
• 0 Every few months 
• 0 Once or twice 
61 [LSD] Have you used Hallucinogens/LSD/Magic Mushrooms in the last 6 months? 
Please choose only one of the following: 
• 0 Yes 
• 0 No 
62 ILSD_howoften] In the last 6 months, how often did you use 
Hallucinogens/LSD/Magic Mushrooms? 
Only answer this question if the following conditions are met: 
Please choose only one of the following: 
• 0 Every day 
• 0 Once a week or more 
• 0 About once a month 
• 0 Every few months 
• 0 Once or twice 
63 [meth] Have you used Meth/amphetamine in the last 6 months? 
Please choose only one of the following: 
• 0 Yes 
• 0 No 
64 Imeth_howoftengn the last 6 months, how often did you use Meth/amphetamine? 
Only answer this question if the following conditions are met: 
Please choose only one of the following: 
• 0 Every day 
• 0 Once a week or more 
• 0 About once a month 
• 0 Every few months 
• 0 Once or twice 
65 Iheroin]Have you used heroin in the  last 6 months? 
Please choose only one of the following: 
• 0 Yes 
• 0 No 
66 Iheroin_howoftenlIn the last 6 months, how often did you use heroin? 
Only answer this question if the following conditions are met: 
Please choose only one of the following: 
• 0 Every day 
• 0 Once a week or more 
• 0 About once a month 
• 0 Every few months 
• 0 Once or twice 
67 Imethadone]Have you used Methadone/buprenorphine for non-medical purposes in 
the last 6 months? 
Please choose only one of the following: 
• 0 Yes 
• 0 No 
68 Imethadone_howoften]In the last 6 months how often did you use 
Methadone/buprenorphine for non-medical purposes? 
Only answer this question if the following conditions are met: 
100 
Please choose only one of the following: 
• 0 Every day 
• 0 Once a week or more 
• 0 About once a month 
• 0 Every few months 
• 0 Once or twice 
69 lopioids]Have you used other opioids (e.g., morphine, oxycodone) for non-medcial 
purposes in the last 6 months? 
Please choose only one of the following: 
• 0 Yes 
• 0 No 
70 [opioids_howoften] 
How often did you use other opioids for non-medical purposes in the last 6 months? 
Only answer this question if the following conditions are met: 
Please choose only one of the following: 
• 0 Every day 
• 0 Once a week or more 
• 0 About once a month 
• 0 Every few months 
• 0 Once or twice 
71 [cocaine]Have you used Cocaine in the last 6 months? 
Please choose only one of the following: 
• 0 Yes 
• 0 No 
72 Icocaine_howoften]In the last 6 months how often did you use Cocaine? 
Only answer this question if the following conditions are met: 
Please choose only one of the following: 
• 0 Every day 
• 0 Once a week or more 
• 0 About once a month 
• 0 Every few months 
• 0 Once or twice 
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73 [ecstasy]Have you used EcStasy in the last 6 months? 
Please choose only one of the following: 
• 0 Yes 
• 0 No 
74 lecstasy_howoften]In the last 6 months, how often did you use Ecstasy? 
Only answer this question if the following conditions are met: 
Please choose only one of the following: 
• 0 Every day 
• 0 Once a week or more 
• 0 About once a month 
• 0 Every few months 
• 0 Once or twice 
PWI 
75 [wellbeing] 
The following questions ask how satisfied you feel, on a scale from zero to 10. Zero 
means you feel completely dissatisfied. 10 means you feel completely satisfied. And the 
middle of the scale is 5, which means you feel neutral, neither satisfied nor dissatisfied. 
Thinking about your own life and personal circumstances, how satisfied are you.... 
Please choose the appropriate response for each item: 
...with your life as a whole? 
...with your standard of living? 
...with your health? 
...with what you are achieving in life? 
...with your personal relationships? 
...with how safe you feel? 
•..with feeling part of your community? 
...with your future security? 
...with your spirituality or religion? 
102 
103 
Appendix Cl: Information Sheet 
Thank you for your interest in this research. This study is being conducted in partial 
fulfillment of a Masters degree for Sophie Marshall under the supervision of Dr. Raimondo 
Bruno at the University of Tasmania. 
Before you decide to participate, it is important for you to understand why the research is 
being done and what it will involve. 
Please take time to read the following information carefully. 
Please contact the researchers by email cuditstudy_2011@yahoo.com.au if you would like 
more information. 
I. What is this study about? 
This study aims to better understand the development of dependence to cannabis. In 
particular, we aim to better understand the possible positive and negative psychological, 
health, and social implications that may occur at different degrees of cannabis use and 
dependency (i.e., people with no problems, mild problems and clear dependence to cannabis). 
This study will help with the development of ways of identifying cannabis problems early 
and the interventions needed to manage cannabis dependence. 
You are invited to participate in this study: 
269. if you are over the age of 18 years old; 
270. live in Australia; and 
271. have used cannabis in the past 6 months. 
2. What will I be asked to do? 
As a participant in this survey, you will be asked to complete an anonymous online survey on 
the positive and negative effects of smoking cannabis, including questions regarding your 
health, lifestyle, other drug use, physical health, mental health, and social interaction. This 
will take about 30-40 minutes to complete. It is important that you understand that your 
involvement in this study is voluntary. If you decide to discontinue participation at any time, 
you can do so by simply closing your web browser. No information will be submitted to the 
researchers until you have completed the survey. 
3. Where will the data be kept? 
All of the survey information/data we obtain from Participants will be kept on a password-
protected computer in the School of Psychology, University of Tasmania, for a period of five 
years. 
4. How will the data be kept secure? 
All survey data will be stored on a password-protected computer. 
5. How and when will the data be destroyed? 
After the study is published all data relating to the study will be electronically stored for five 
years. After this period, or when the data is no longer of use, all survey data will be deleted. 
6. Are there any possible benefits from participation in this study? 
Participating in this study may result in individuals having a greater understanding of their 
cannabis use and the possible effects that this may have on their wellbeing. By participating 
in this study, you are providing important and valuable information in an area of research that 
is relevant to you. Your participation will help us gain important information that will assist 
us to better understand the positive and negative effects that Australians experience from 
their cannabis use and how this relates to different levels of use as well as among those with 
dependence problems. This information will be valuable in the development of community 
intervention programs aimed at reducing the harms some people experience with cannabis 
use. 
Additionally, to thank you for your time, upon completion you may choose to enter a draw 
to win one of three $500 JB-HiFi gift vouchers! 
7.Are there any possible risks involved in participating in this study? 
There are no specific risks anticipated with taking part in this study. However, should you 
become uncomfortable or upset whilst completing the survey, or feel you'd like to talk to 
someone about your cannabis use, below are some contact details of services that are 
available 24 hours a day, 7 days a week: 
Cannabis Information & Helpline: 1800 30 40 50 
Counselling Online: www.counsellingonline.org.au  
Beyondblue: 13 11 11 
8. How will your confidentiality and privacy be protected? 
None of the questions asked in the questionnaire will provide information that could directly 
identify you as an individual, and you are free to decline to answer any question you are not 
comfortable with. We do not collect your IP address or referrer URL, neither do we 
timestamp your answers. To protect the security of transmission of information between your 
computer and our server, our server uses an encryption which is backed by AusCERT 
certificate with 2048 bits long key. This is the same level of encryption used by banks and the 
Australian Tax Office, which means that your data cannot be intercepted during transmission. 
As a further degree of protection, you may also choose to use an anonymiser, which will 
mask your IP address. This will mean that the computer you are using will be unidentifiable. 
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Anonymisers work by inserting a 'fake computer' between your computer and our server, 
therefore masking your IP address. For more information see: http://proxy.org . Together, 
these steps mean that your data can be safely provided anonymously. 
9. What i f I have questions or concerns about this research? 
If you would like to discuss any aspect of this study please feel free to contact either of the 
researchers by email at cuditstudy_2011@yahoo.com.au . If you would like to view the results 
of this research, this can occur at the conclusion of this research and the results will be 
published online at the survey website. Additionally, if you require further information or 
want to discuss the results, you may email the researchers. 
This study has been approved by the Tasmanian Social Science Human Research Ethics 
Committee. If you have concerns or complaints about the conduct of this study you can 
contact the Executive Officer of the HREC (Tasmania) Network on +61(0)36226 7479 or 
email human.ethics@utas.edu.au . The Executive Officer is the person nominated to receive 
complaints from research participants. You will need to quote H0012077. 
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Appendix C2: Consent Form 
How do I participate? 
By clicking the button below, you indicate that you have read the information on this page 
and you are agreeing to participate in this research study. If you do not wish to participate, we 
thank you for your interest. 
1.I have read and understood the 'Information Sheet' for this study. 
2. I understand the nature and possible effects of this study. 
3. I understand that this study involves answering questions about drug use, physical health, 
mental health, and social interactions. 
4.1 understand that all questions are optional and that I may choose to not answer any 
questions that I am uncomfortable with. 
5. I understand that all research data will be securely stored on a password-protected server at 
the University of Tasmania. 
6. I understand that my participation is voluntary and that I cannot be identified in any way. 
I agree with the above statements and wish to participate in the survey. _ 
I IA
g 
ree 
There are 75 questions in this survey 
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Appendix C3: Prize Draw Invitation 
Thank you for taking the time to complete the questionnaire, it is very much appreciated and 
the information you have provided will be very valuable to help the researchers better 
understand the effects cannabis has on peoples' functioning, health, and general wellbeing. 
The researchers would like to now offer you the opportunity to enter a prize draw to 
win one of three $500 JB Hi-Fi Gift Vouchers! 
By clicking on the "Enter Prize Draw" link below, you will be directed to a separate webpage 
where you will be asked to provide a valid, but anonymous email address. If you would not 
like to enter the draw simply exit this page. Thank you once again for your time. 
If you would like to enter the prize draw, you may write your valid email account in the space 
provided below. Please note that to protect your anonymity, we request that you use an email 
account that is not connected to your name in any way. If required, you may create an 
anonymous free account by accessing www.hotmail.com or www.gmail.com . 
Please type your anonymous email address in the box provided 
Please re-type your anonymous email address in the box provided 
